BLOOD CANCER UNITED INC: Form 990, tax year 2013
View the entire original 990 at ProPublica ↗
- Organization
- BLOOD CANCER UNITED INC (EIN 13-5644916)
- Tax period
- 2013-07-01 to 2014-06-30
- Filed
- 2015-02-07
- IRS object ID
- 201520389349300502
- Schema version
- 2013v4.0
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule C
- Schedule D
- Schedule F
- Schedule G
- Schedule I
- Schedule J
- Schedule M
- Schedule O
- Schedule R
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2015-02-07T08:41:10-06:00 | ReturnTs |
| Tax Period End | 2014-06-30 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 135565207 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | KPMG LLP | BusinessNameLine1 |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 345 PARK AVENUE | AddressLine1 |
| City | NEW YORK | City |
| State | NY | State |
| ZIP Code | 101540102 | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2013-07-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 135644916 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | THE LEUKEMIA & LYMPHOMA SOCIETYINC | BusinessNameLine1 |
| Business Name Line2 | INC | BusinessNameLine2 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | LEUK | BusinessNameControlTxt |
| Phone | 9149495213 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1311 MAMARONECK AVENUE | AddressLine1 |
| Address Line2 | ROOM/SUITE 310 | AddressLine2 |
| City | WHITE PLAINS | City |
| State | NY | State |
| ZIP Code | 10605 | ZIPCode |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | ROSEMARIE LOFFREDO | PersonNm |
| Person Title | CAO & CFO | PersonTitleTxt |
| Phone | 9149495213 | PhoneNum |
| Signature | 2015-02-06 | SignatureDt |
| Discuss With Paid Preparer | Yes (true) | DiscussWithPaidPreparerInd |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | KPMG LLP | PreparerPersonNm |
| PTIN | P01249521 | PTIN |
| Phone | 2127589700 | PhoneNum |
| Preparation | 2015-02-07 | PreparationDt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2013 | TaxYr |
| Build TS | 2016-02-25 16:41:14Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | LOUIS J DEGENNARO PRESIDENT CEO | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1311 MAMARONECK AVENUE | AddressLine1 |
| City | WHITE PLAINS | City |
| State | NY | State |
| ZIP Code | 10605 | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $422,686,143 | GrossReceiptsAmt |
| Group Return For Affiliates | false | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | WWW.LLS.ORG | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 1949 | FormationYr |
| Legal Domicile State | NY | LegalDomicileStateCd |
| Activity Or Mission | OUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES. | ActivityOrMissionDesc |
| Voting Members Governing Body | 28 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 28 | VotingMembersIndependentCnt |
| Total Employee | 1439 | TotalEmployeeCnt |
| Total Volunteers | 3000000 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| PY Contributions Grants | $279,789,665 | PYContributionsGrantsAmt |
| CY Contributions Grants | $302,437,152 | CYContributionsGrantsAmt |
| CY Program Service Revenue | $0 | CYProgramServiceRevenueAmt |
| PY Investment Income | $8,133,222 | PYInvestmentIncomeAmt |
| CY Investment Income | $6,995,117 | CYInvestmentIncomeAmt |
| PY Other Revenue | $2,435,580 | PYOtherRevenueAmt |
| CY Other Revenue | $663,718 | CYOtherRevenueAmt |
| PY Total Revenue | $290,358,467 | PYTotalRevenueAmt |
| CY Total Revenue | $310,095,987 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $117,726,007 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $130,249,475 | CYGrantsAndSimilarPaidAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $90,034,581 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $94,185,722 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $10,134,488 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $7,178,370 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $50,314,811 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $89,083,589 | PYOtherExpensesAmt |
| CY Other Expenses | $85,584,715 | CYOtherExpensesAmt |
| PY Total Expenses | $306,978,665 | PYTotalExpensesAmt |
| CY Total Expenses | $317,198,282 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | -$16,620,198 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | -$7,102,295 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $236,325,556 | TotalAssetsBOYAmt |
| Total Assets EOY | $242,581,527 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $135,316,123 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $145,444,419 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $101,009,433 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $97,137,108 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | OUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES. | MissionDesc |
| Significant New Program Srvc | false | SignificantNewProgramSrvcInd |
| Significant Change | false | SignificantChangeInd |
| Expense | $82,095,311 | ExpenseAmt |
| Grant | $78,325,341 | GrantAmt |
| Desc | A) RESEARCH PROGRAMS: WITH ADVISORY INPUT FROM RECOGNIZED BIOMEDICAL RESEARCH EXPERTS, LLS FUNDS EXEMPLARY PROJECTS ACROSS THE ENTIRE RESEARCH CONTINUUM RELEVANT TO IMPROVED OUTCOMES FOR BLOOD CANCER PATIENTS, FROM BASIC LABORATORY SCIENCE THROUGH CLINICAL TRIALS, AND FROM INVESTIGATOR-INITIATED RESEARCH TO PRIVATE-SECTOR DRUG DEVELOPMENT ALLIANCES. LLS IS DELIBERATE AND PURPOSEFUL IN FINDING AND SUPPORTING RESEARCH THAT IS MOST LIKELY TO HELP PATIENTS AS SOON AS POSSIBLE. (CONTINUED ON SCHEDULE O) TO DATE, LLS HAS INVESTED ALMOST 1 BILLION IN RESEARCH AIMED AT HELPING ALL BLOOD CANCER PATIENTS LIVE BETTER, LONGER LIVES. WE WILL CONTINUE TO SUPPORT RESEARCH THROUGH OUR INNOVATIVE AND INTEGRATED FUNDING PROGRAMS, UNTIL EVERY PATIENT HAS A SAFE AND EFFECTIVE THERAPY. IN FISCAL YEAR 2014, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 7 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 78 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. OUR CRITICAL ROLE LLS PROGRAMS ACCELERATE RELEVANT RESEARCH OUTCOMES BY: - BUILDING A FOCUSED RESEARCH WORK-FORCE: ASSURING THE NEXT ROUND OF BREAKTHROUGHS REQUIRES THAT YOUNG INVESTIGATORS BE ENCOURAGED TO WORK IN BLOOD CANCER RESEARCH FIELDS. - TURNING DISCOVERIES INTO NEW THERAPIES: FUNDAMENTAL NEW FINDINGS CAN BE TRANSLATED INTO SAFE AND EFFECTIVE TREATMENTS THAT CAN ULTIMATELY PROLONG AND ENHANCE PATIENT LIVES. - SUPPORTING SYNERGY: LARGE GRANTS AND CONTRACTS ENABLE SCIENTISTS IN ACADEMIA AND THE PRIVATE-SECTOR TO COLLABORATE, COMBINING RESOURCES AND EXPERTISE TO PRODUCE MORE AND FASTER ADVANCES. - FILLING A VOID: RESEARCH PROJECTS THAT ARE HIGH-RISK AND/OR ADDRESS RARE CANCERS ARE LESS LIKELY TO BE FUNDED BY GOVERNMENT AGENCIES OR FOR-PROFIT COMPANIES, BUT MAY PROVIDE IMPORTANT ADVANCES. - SPEEDING NEW TREATMENTS TO PATIENTS: PARTNERING WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES CAN ADVANCE PROMISING THERAPIES THROUGH CLINICAL TESTING, FASTER. PAST ADVANCES MADE WITH LLS RESEARCH FUNDING GENEROUS DONORS HAVE HELPED LLS SUPPORT RESEARCH THAT HAS ALREADY BENEFITED BLOOD CANCER PATIENTS AND MANY OTHERS. ADVANCES INCLUDE: - MULTI-DRUG THERAPIES THAT ARE MORE EFFECTIVE THAN TREATMENTS WITH SINGLE ANTI-CANCER AGENTS, - BONE MARROW / STEM CELL TRANSPLANTATION AND SUPPORTIVE CARE TREATMENTS FOR PATIENTS WHO RELAPSE DESPITE THE BEST AVAILABLE THERAPY, - TESTS THAT DISTINGUISH SPECIFIC CHARACTERISTICS OF PARTICULAR BLOOD CANCERS FOR ACCURATE DIAGNOSIS OF CANCER SUBTYPES, AND FOR "RISK STRATIFICATION" TO SELECT AN OPTIMAL THERAPY. TARGETED THERAPY RESEARCH DISCOVERING THE MOLECULAR ABNORMALITIES THAT CAUSE PARTICULAR TYPES OF BLOOD CANCER HAS BEEN USEFUL IN DIAGNOSIS AND RISK STRATIFICATION, AND IN NEW "TARGETED DRUG" DEVELOPMENT. LLS-FUNDED INVESTIGATORS HAVE HELPED ADVANCE MOLECULARLY TARGETED TREATMENTS THAT CAN SELECTIVELY KILL BLOOD CANCER CELLS VERSUS NORMAL CELLS. MANY OF THESE NEW TREATMENTS BENEFIT NOT ONLY BLOOD CANCER PATIENTS, BUT ALSO PATIENTS WITH OTHER DISEASES. FOR EXAMPLE: - GLEEVEC IS FDA-APPROVED FOR PATIENTS OF ALL AGES WITH CHRONIC MYELOID LEUKEMIA (CML), AND IS ALSO APPROVED FOR PATIENTS WITH ONE FORM OF ACUTE LYMPHOID LEUKEMIA (ALL), MYELODYSPLASTIC SYNDROMES (MDS), MYELOPROLIFERATIVE DISORDERS AND RARE FORMS OF STOMACH AND SKIN CANCERS. RELATED DRUGS, SPRYCEL AND TASIGNA, ARE APPROVED FOR PATIENTS WHO DO NOT BENEFIT FROM GLEEVEC. ONE OR MORE OF THESE DRUGS ARE ALSO SHOWING PROMISE FOR PATIENTS WITH VARIOUS LYMPHOMAS, ACUTE MYELOID LEUKEMIA (AML), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND OTHER CANCERS, INCLUDING BRAIN, BREAST, HEAD-AND-NECK, LUNG, PANCREATIC, AND PROSTATE CANCERS, AND PATIENTS WITH OTHER DISEASES INCLUDING ALZHEIMER'S, ASTHMA AND PULMONARY HYPERTENSION. - RITUXAN WAS THE FIRST FDA-APPROVED, ANTI-CANCER ANTIBODY DRUG, DEVELOPED FOR PATIENTS WITH FORMS OF B-CELL NON-HODGKIN LYMPHOMA (NHL). IT IS NOW ALSO APPROVED FOR CLL PATIENTS AND AS A "MAINTENANCE" THERAPY FOR FOLLICULAR LYMPHOMA PATIENTS, AND SHOWING PROMISE FOR PATIENTS WITH ALL AND AFTER STEM CELL TRANSPLANTATION. IN ADDITION, IT IS APPROVED FOR TREATING PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS AND TWO OTHER TYPES OF AUTOIMMUNE DISEASES. A RELATED ANTIBODY DRUG, ARZERRA, IS APPROVED FOR CLL PATIENTS AND SHOWING WIDER PROMISE. - VELCADE, THALIDOMID AND REVLIMID ARE FDA-APPROVED FOR PATIENTS WITH MYELOMA AND ARE ALSO HELPING SOME PATIENTS WITH HODGKIN LYMPHOMA AND NHL. KRYPOLIS WAS RECENTLY APPROVED FOR MYELOMA PATIENTS FOR WHOM AT LEAST TWO PRIOR THERAPIES WERE INSUFFICIENT. ONE OR MORE OF THESE DRUGS ARE NOW BEING TESTED FOR PATIENTS WITH T-CELL AND B-CELL FORMS OF LYMPHOMA, ACUTE LEUKEMIAS, AS WELL AS AIDS-RELATED KAPOSI SARCOMA AND BRAIN, BREAST, COLORECTAL, HEAD-AND-NECK, KIDNEY, LIVER, LUNG, OVARIAN AND PROSTATE CANCERS, AND ALZHEIMER'S DISEASE. - ISTODAX, ZOLINZA, DACOGEN AND VIDAZA TARGET SMALL CHEMICAL, "EPIGENETIC" CHANGES. THE FIRST TWO DRUGS ARE APPROVED FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS; THE LATTER DRUGS ARE APPROVED FOR MDS PATIENTS. ONE OR MORE OF THESE DRUGS ARE BEING TESTED FOR PATIENTS WITH ALL, AML, CML, CLL, MYELOMA AND FORMS OF NHL, AFTER STEM CELL TRANSPLANTATION, AND FOR PATIENTS WITH BREAST, BRAIN, KIDNEY, COLORECTAL, HEAD-AND-NECK, LUNG, STOMACH, PROSTATE AND OVARIAN CANCERS, MELANOMA AS WELL AS SICKLE CELL DISEASE AND PERSISTENT HIV INFECTIONS. - ADCETRIS WAS APPROVED IN 2011, AND IN JANUARY 2012. IT IS AN ANTIBODY- DRUG CONJUGATE THAT COMBINES AN ANTI-CD30 ANTIBODY AND THE CYTOTOXIC DRUG MONOMETHYL AURISTATIN E (MMAE). IT IS AN ANTI-NEOPLASTIC AGENT USED IN THE TREATMENT OF HODGKIN LYMPHOMA AFTER FAILURE OF AUTOLOGOUS STEM CELL TRANSPLANT OR THOSE WHO ARE NOT ELIGIBLE FOR ASCT AFTER FAILURE OF AT LEAST 2 MUTIAGEN CHEMOTHERAPY REGIMENS. ADCETRIS WAS ALSO APPROVED FOR SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA WITH FAILURE OF AT LEAST ONE PRIOR TREATMENT. - GAZYVA IS A HUMANIZED MONOCLONAL ANTIBODY USED AS A COMBINATION TREATMENT WITH CHLORAMBUCIL TO TREAT PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA. IT WAS APPROVED BY THE FDA IN NOVEMBER 2013 AND BY THE EHA IN JULY 2014. - IMBRUVICA IS AN ORAL SMALL MOLECULE INHIBITOR AGIANST BTK KINASE. IT WAS FIRST APPROVED BY THE US FDA ON NOVEMBER 13, 2013 FOR THE TREATMENT OF MANTLE CELL LYMPHOMA PATIENTS WHO HAVE RECIEVED AT LEAST ONE PRIOR TREATMENT. ON FEB. 12, 2014 THE US FDA EXPANDED THE APPROVED USE OF THE DRUG TO CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ADDITIONALLY, IT RECEIVED FURTHER EXPANSION TO TREAT 17P DELETION IN CLL WITH OR WITHOUT PRIOR THERAPY. - ZYDELIG IS AN ORAL SMALL MOLECULE INHIBITOR THAT BLOCKS THE DELTA ISOFORM OF THE ENZYME PHOSPHOINOSITIDE 3-KINASE. IT WAS APPROVED BY THE FDA IN JULY 2014 TO TREAT RELAPSED/REFRACTORY CLL IN COMBINATION WITH RITUXAN. IT WAS ALSO APPROVED TO USE AS A MONOTHERAPY FOR RELAPSED MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA. OTHER ACTIVE RESEARCH DIRECTIONS LLS-FUNDED RESEARCHERS ARE ALSO EXPLORING OTHER AREAS OF RESEARCH THAT HOLD PROMISE FOR PATIENTS: - NOVEL STEM CELL TRANSPLANTATION PROCEDURES: THESE INCLUDE SO-CALLED "MINI" TRANSPLANTS THAT USE LESS TOXIC PRE-TRANSPLANT TREATMENTS AND ENGINEERED DONOR CELLS THAT HELP REDUCE POST-TRANSPLANT COMPLICATIONS, MAKING THESE POTENTIALLY CURATIVE TREATMENTS AVAILABLE TO MORE PATIENTS. - IMMUNOTHERAPIES: INCLUDING ANTIBODIES, VACCINES AND ENGINEERED IMMUNE CELLS, THESE TARGETED THERAPIES HELP A PATIENT'S IMMUNE SYSTEM FIGHT INFECTIONS AND KILL RESIDUAL CANCER CELLS, PROLONGING REMISSIONS, AND PERHAPS ONE DAY REPLACING TOXIC CHEMOTHERAPIES. - DIAGNOSTICS: NEW TECHNOLOGIES MAKE IT POSSIBLE TO CHARACTERIZE THE ABNORMALITIES IN INDIVIDUAL CANCER CASES IN MOLECULAR DETAIL. THIS INFORMATION CAN BE USED TO HELP CHOOSE THE BEST POSSIBLE TREATMENT FOR EACH PATIENT, ESPECIALLY AS MORE TARGETED THERAPIES BECOME AVAILABLE. - QUALITY OF LIFE RESEARCH: THESE STUDIES INCREASE OUR UNDERSTANDING OF HOW SPECIFIC TREATMENTS CAN CAUSE DEBILITATING SIDE-EFFECTS, INCLUDING LATE-EFFECTS, AND WHICH PATIENTS ARE AT RISK FOR DEVELOPING THESE COMPLICATIONS, SO THAT THEY CAN BE BETTER MANAGED OR EVEN PREVENTED. DRIVING RESEARCH TO ADDRESS UNMET MEDICAL NEEDS LLS CONTINUES TO SOLICIT AND SUPPORT RESEARCH FOCUSED ON IMPROVING BLOOD CANCER PATIENTS' QUALITY OF LIFE AFTER TODAY'S CURATIVE THERAPIES. ALSO IN 2014, FOR THE THIRD YEAR, LLS ACTIVELY RECRUITED RESEARCH PROPOSALS IN SIX OTHER UNDERDEVELOPED RESEARCH AREAS IN WHICH PROGRESS IS LIKELY TO IMPROVE OUTCOMES FOR PATIENTS WITH PARTICULARLY URGENT NEEDS. NEW RESEARCH IS FOCUSED ON: - DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES FOR PATIENTS WITH NON- CUTANEOUS T-CELL LYMPHOPROLIFERATIVE DISORDERS - DEVELOP NOVEL TARGETED THERAPIES FOR CLL PATIENTS, WITH REAL CURATIVE POTENTIAL - DEVELOP NOVEL TREATMENT STRATEGEIES FOR MDS AND AML PATIENTS - DEVELOP NOVEL TARGETED THERAPIES FOR PATIENTS WITH HIGH-RISK MYELOMA - DEVELOPMENT OF NEW-TARGETED THERAPIES FOR INDOLENT LYMPHOMA PATIENTS - DEFINE GENETIC/MOLECULAR PREDISPOSITIONS | Desc |
Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $96,728,148 | ExpenseAmt |
| Grant | $51,924,134 | GrantAmt |
| Desc | B) PATIENT & COMMUNITY SERVICES: AN ESTIMATED 1,129,813 PEOPLE ACROSS THE UNITED STATES (US) CURRENTLY BATTLE LEUKEMIA, LYMPHOMA AND MYELOMA. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) OFFERS A FREE, COMPREHENSIVE ARRAY OF SERVICES TO BLOOD CANCER PATIENTS AND THEIR FAMILIES, VOLUNTEER CAREGIVERS AND ADVOCATES, HEALTHCARE PROFESSIONALS AND THE PUBLIC. (CONTINUED ON SCHEDULE O) LLS IS COMMITTED TO PROVIDING THE MOST ACCURATE AND UP-TO-DATE BLOOD CANCER INFORMATION. PROFESSIONAL VOLUNTEER CLINICAL ADVISORS WORK WITH LLS STAFF TO REVIEW ALL OF THE INFORMATION LLS PROVIDES THROUGH HEALTHCARE PROFESSIONAL AND PATIENT EDUCATION PROGRAMS, PUBLICATIONS AND THE LLS WEBSITE. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. LLS PUBLISHES AN ANNUAL COMPILATION OF DATA AVAILABLE FOR BLOOD CANCERS, INCLUDING THE ESTIMATED NUMBERS OF NEW BLOOD CANCER CASES AND DEATHS, THE MOST RECENT STATISTICS AVAILABLE FOR INCIDENCE, MORTALITY AND SURVIVAL; AND CURRENT AND ACCURATE INFORMATION ABOUT SYMPTOMS, RISK FACTORS AND TREATMENT. PUBLICATIONS AN EXTENSIVE CATALOG OF EDUCATION MATERIALS IS OFFERED FREE-OF-CHARGE TO PATIENTS AND HEALTHCARE PROFESSIONALS. EACH YEAR, LLS DISTRIBUTES BOOKLETS, BROCHURES, FACT SHEETS, EDUCATION PROGRAM TRANSCRIPTS AND DVDS THROUGH THE INFORMATION RESOURCE CENTER AND LLS CHAPTERS. MANY MATERIALS ARE ALSO AVAILABLE TO VIEW AND DOWNLOAD AT WWW.LLS.ORG/RESOURCECENTER. DOWNLOADABLE MATERIALS ARE AVAILABLE IN ENGLISH, SPANISH AND FRENCH. - 742,148 PRINTED BOOKLETS, BROCHURES, FACT SHEETS, EDUCATION PROGRAM TRANSCRIPTS AND DVDS DISTRIBUTED IN 2014. FINANCIAL ASSISTANCE IN 2014, A COMBINED 51,924,134 WAS DISBURSED TO PATIENTS THROUGH THE LLS PATIENT FINANCIAL AID (2,523,615),CO-PAY ASSISTANCE PROGRAMS (49,246,019) AND THE LLS PATIENT TRAVEL ASSISTANCE PROGRAM (154,500). PATIENT FINANCIAL ASSISTANCE PROGRAMS FOR MORE THAN 47 YEARS, LLS HAS HELPED PATIENTS DEMONSTRATING SIGNIFICANT NEED TO OBTAIN FINANCIAL ASSISTANCE TO COVER A PORTION OF THEIR TREATMENT COSTS. THE LLS PATIENT FINANCIAL ASSISTANCE PROGRAM PROVIDES A LIMITED AMOUNT OF FINANCIAL ASSISTANCE TO HELP PATIENTS WITH SIGNIFICANT FINANCIAL NEED AND WHO ARE UNDER A DOCTOR'S CARE FOR A CONFIRMED BLOOD CANCER DIAGNOSIS. PATIENT FINANCIAL ASSISTANCE FUNDS ARE SUBJECT TO AVAILABILITY. - 25,854 PATIENTS RECEIVED PATIENT FINANCIAL ASSISTANCE IN 2014. CO-PAY ASSISTANCE PROGRAM THIS CO-PAY ASSISTANCE PROGRAM HELPS PATIENTS WITH MANY KINDS OF BLOOD CANCERS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO-PAYMENT OBLIGATIONS RELATED TO TREATING THEIR CANCER. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUND AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. FOR MORE INFORMATION CALL, (877) LLS-COPAY (877) 557-2672 OR VISIT WWW.LLS.ORG/COPAY. - 18,640 PATIENTS RECEIVED LLS CO-PAY ASSISTANCE IN 2014 COMMUNITY PROGRAMS EACH LLS CHAPTER OFFICE IS STAFFED WITH A PATIENT SERVICES MANAGER (PSM) WHO OVERSEES SERVICES TO PATIENTS AND THEIR FAMILIES, CAREGIVERS AND HEALTHCARE PROFESSIONALS. PSMS ARE HEALTHCARE PROFESSIONALS, OFTEN WITH A BACKGROUND IN ONCOLOGY NURSING OR SOCIAL WORK. PSMS SERVE AS LIAISONS WITH COMMUNITY AND REGIONAL ONCOLOGY/HEMATOLOGY HEALTHCARE PROFESSIONALS AND TREATMENT CENTERS.COMMUNITY-BASED EDUCATION AND OUTREACH, SUPPORT AND PUBLIC POLICY AND ADVOCACY PROGRAMS ARE AVAILABLE. - 27,459 PATIENT AND CAREGIVER PARTICIPANTS ACROSS THE US IN 2014 - 10,798 HEALTHCARE PROFESSIONAL PARTICIPANTS ACROSS THE US IN 2014 PROGRAMS FOR CHILDREN AND YOUNG ADULTS THE TRISH GREENE BACK TO SCHOOL PROGRAM FOR CHILDREN WITH CANCER FOCUSES ON INCREASING COMMUNICATION AMONG HEALTHCARE PROFESSIONALS, PARENTS, PATIENTS AND SCHOOL PERSONNEL TO SUPPORT CHILDREN, ADOLESCENTS AND YOUNG ADULTS LIVING WITH CANCER. PRINTED LITERATURE, VIDEOS AND OTHER MATERIALS TO AID THE PROCESS ARE AVAILABLE IN COMMUNITIES THROUGHOUT THE US AND CANADA VIA LLS CHAPTER OFFICES. THE PROGRAM INCLUDES STAYING CONNECTED: FACILITATING THE LEARNING EXPERIENCE DURING AND AFTER CANCER TREATMENT. THIS EDUCATION PROGRAM FOR SCHOOL PERSONNEL, HEALTHCARE PROFESSIONALS AND PARENTS DESCRIBES PHYSICAL, COGNITIVE AND PSYCHOSOCIAL SHORT-AND LONG-TERM EFFECTS THAT CHILDREN, ADOLESCENTS AND YOUNG ADULTS MAY EXPERIENCE DURING AND AFTER TREATMENT. THE PROGRAM OFFERS GUIDANCE AND NUMEROUS RESOURCES TO HELP CHILDREN, ADOLESCENTS AND YOUNG ADULTS CONTINUE THEIR EDUCATION DURING AND AFTER TREATMENT. - 1,075 SCHOOL PERSONNEL, HEALTHCARE PROFESSIONALS AND PARENTS PARTICIPATED IN THE 22 STAYING CONNECTED PROGRAMS ACROSS THE US AND CANADA IN 2014. FAMILY SUPPORT GROUPS LLS HAS DEVELOPED 344 FAMILY SUPPORT GROUPS AT CHAPTERS THROUGHOUT THE US AND CANADA. LLS ALSO HAS 618 VOLUNTEER SUPPORT GROUP FACILITATORS WITH BACKGROUNDS IN ONCOLOGY NURSING OR SOCIAL WORK. GROUPS ARE GUIDED BY TWO VOLUNTEER ONCOLOGY HEALTH PROFESSIONALS, PROVIDING INFORMATION AND SUPPORT AND ENCOURAGING GREATER COMMUNICATION AMONG PATIENTS, FAMILIES, FRIENDS AND HEALTHCARE PROFESSIONALS. - 13,811 PARTICIPANTS IN FAMILY SUPPORT GROUPS ACROSS THE US IN 2014 PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM FIRST CONNECTION IS A PROGRAM THAT LINKS NEWLY DIAGNOSED PATIENTS TO A PEER VOLUNTEER WHO HAS EXPERIENCED A SIMILAR DIAGNOSIS. A TRAINED PATIENT-VOLUNTEER CURRENTLY IN REMISSION CONTACTS THE NEW PATIENT TO SHARE INFORMATION AND SUPPORT. THIS PROGRAM IS AVAILABLE THROUGH LLS CHAPTERS. - 5,616 FIRST CONNECTIONS ACROSS THE US IN 2014. | Desc |
Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $42,730,205 | ExpenseAmt |
| Desc | C) PUBLIC HEALTH EDUCATION: INFORMATION AND EDUCATION INFORMATION RESOURCE CENTER PAYING FOR MEDICAL CARE, MAKING TREATMENT CHOICES, COMMUNICATING WITH HEALTHCARE PROVIDERS, FAMILY MEMBERS AND FRIENDS-THESE ARE SOME OF THE STRESSES THAT COME WITH A CANCER DIAGNOSIS. (CONTINUED ON SCHEDULE O) LLS INFORMATION SPECIALISTS ARE MASTER'S LEVEL ONCOLOGY SOCIAL WORKERS, NURSES AND HEALTH EDUCATORS WHO PROVIDE HELP WITH DISEASE, TREATMENT AND CLINICAL TRIAL INFORMATION AND SUPPORT. LLS INFORMATION SPECIALISTS CONDUCT CLINICAL-TRIAL SEARCHES TO HELP PATIENTS WORK WITH THEIR DOCTORS TO FIND OUT ABOUT SPECIFIC CLINICAL TRIALS. PATIENTS, FAMILIES AND HEALTHCARE PROFESSIONALS MAY SPEAK TO AN INFORMATION SPECIALIST AT (800) 955-4572 MONDAY THROUGH FRIDAY, 9 A.M. TO 9 P.M., ET, EMAIL INFOCENTER@LLS.ORG OR CHAT ONE-ON-ONE VIA THE LLS WEBSITE. THE INFORMATION RESOURCE CENTER OFFERS TRANSLATION SERVICES IN MORE THAN 165 LANGUAGES. - 48,326 INQUIRIES IN 2014 THE LLS WEBSITE THE LLS WEBSITE, WWW.LLS.ORG, FULFILLS A WIDE VARIETY OF EDUCATION AND INFORMATION NEEDS. VISITORS CAN PERSONALIZE THEIR WEB PAGES TO THEIR LOCATION TO KEEP CURRENT WITH DISEASE-SPECIFIC UPDATES AND COMMUNITY EDUCATION AND SUPPORT ACTIVITIES. THE WEBSITE PROVIDES ACCESS TO LLS PROGRAMS AND SERVICES, INCLUDING CO-PAY ASSISTANCE, THE MOST CURRENT AND ACCURATE INFORMATION AND STATISTICS, WEEKLY FACILITATED ONLINE CHATS, NATIONAL TELEPHONE AND WEB EDUCATION PROGRAMS, PUBLICATIONS IN ENGLISH, SPANISH AND FRENCH, AND CLINICAL-TRIAL SEARCHES VIA AN ONLINE CLINICAL- TRIAL SEARCH SERVICE THAT OFFERS PATIENTS AND CAREGIVERS IMMEDIATE ACCESS TO LISTINGS OF BLOOD CANCER CLINICAL TRIALS. PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS CAN INTERACT WITH LLS AND ONE ANOTHER THROUGH SOCIAL NETWORKING, PODCASTS AND ENEWSLETTERS. NATIONAL TELEPHONE/ WEB EDUCATION PROGRAMS LLS SPONSORS TELEPHONE AND WEB EDUCATION PROGRAMS FOR PATIENTS, CAREGIVERS, SURVIVORS AND HEALTHCARE PROFESSIONALS ABOUT LEUKEMIA, LYMPHOMA, MYELOMA AND MYELODYSPLASTIC SYNDROMES. IN 2014, 9 LLS NATIONAL EDUCATION PROGRAMS FEATURED DISEASE-SPECIFIC UPDATES AND INFORMATION ABOUT SUPPORT AND TREATMENT OPTIONS FROM WORLD RENOWNED CLINICAL EXPERTS. OPPORTUNITIES ARE PROVIDED TO ASK QUESTIONS OF EXPERTS DURING THESE PROGRAMS. THESE PROGRAMS OFFER CONTINUING EDUCATION CREDITS FOR NURSES AND SOCIAL WORKERS. LLS ALSO SPONSORS A RANGE OF PROFESSIONAL EDUCATION PROGRAMS. RECENT PROGRAMS EXPLORED THE ADMINISTRATION AND MANAGEMENT OF CURRENT THERAPIES FOR HEMATOLOGIC MALIGNANCIES AND COMMUNICATION AMONG PRIMARY CARE PROVIDERS AND HEMATOLOGISTS/ONCOLOGISTS IN MANAGING PATIENTS WITH HEMATOLOGIC CANCER. UPCOMING PROGRAMS ARE POSTED AT WWW.LLS.ORG/PROGRAMS AND ARCHIVES OF PAST PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PASTPROGRAMS. PROFESSIONAL EDUCATION PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PROFESSIONALED. LLS ALSO OFFERS DISEASE-SPECIFIC WEBCASTS PRESENTED BY WORLD RENOWNED CLINICAL EXPERTS. THESE CAN BE ACCESSED AT WWW.LLS.ORG/WEBCASTS. | Desc |
Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $19,047,085 | ExpenseAmt |
| Desc | D) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. | Desc |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Prog Srvc Expense | $19,047,085 | TotalOtherProgSrvcExpenseAmt |
| Total Program Service Expenses | $240,600,749 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (true) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (true) | ScheduleBRequiredInd |
| Political Campaign Acty | false | PoliticalCampaignActyInd |
| Lobbying Activities | Yes (true) | LobbyingActivitiesInd |
| Subject To Proxy Tax | false | SubjectToProxyTaxInd |
| Donor Advised Fund | false | DonorAdvisedFundInd |
| Conservation Easements | false | ConservationEasementsInd |
| Collections Of Art | Yes (true) | CollectionsOfArtInd |
| Credit Counseling | false | CreditCounselingInd |
| Temp Or Permanent Endowments | Yes (true) | TempOrPermanentEndowmentsInd |
| Report Land Building Equipment | Yes (true) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | Yes (true) | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | false | ReportProgramRelatedInvstInd |
| Report Other Assets | false | ReportOtherAssetsInd |
| Report Other Liabilities | false | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | Yes (true) | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | false | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | Yes (true) | ConsolidatedAuditFinclStmtInd |
| School Operating | false | SchoolOperatingInd |
| Foreign Office | Yes (true) | ForeignOfficeInd |
| Foreign Activities | Yes (true) | ForeignActivitiesInd |
| More Than5000 K To Org | Yes (true) | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | false | MoreThan5000KToIndividualsInd |
| Professional Fundraising | Yes (true) | ProfessionalFundraisingInd |
| Fundraising Activities | Yes (true) | FundraisingActivitiesInd |
| Gaming Activities | Yes (true) | GamingActivitiesInd |
| Operate Hospital | false | OperateHospitalInd |
| Grants To Organizations | Yes (true) | GrantsToOrganizationsInd |
| Grants To Individuals | Yes (true) | GrantsToIndividualsInd |
| Schedule J Required | Yes (true) | ScheduleJRequiredInd |
| Tax Exempt Bonds | false | TaxExemptBondsInd |
| Engaged In Excess Benefit Trans | false | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | false | PYExcessBenefitTransInd |
| Loan Outstanding | false | LoanOutstandingInd |
| Grant To Related Person | false | GrantToRelatedPersonInd |
| Business Rln With Org Mem | false | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | false | BusinessRlnWithFamMemInd |
| Business Rln With Officer Ent | false | BusinessRlnWithOfficerEntInd |
| Deductible Non Cash Contri | Yes (true) | DeductibleNonCashContriInd |
| Deductible Art Contribution | false | DeductibleArtContributionInd |
| Terminate Operations | false | TerminateOperationsInd |
| Partial Liquidation | false | PartialLiquidationInd |
| Disregarded Entity | false | DisregardedEntityInd |
| Related Entity | Yes (true) | RelatedEntityInd |
| Related Organization Ctrl Ent | Yes (true) | RelatedOrganizationCtrlEntInd |
| Transaction With Control Ent | Yes (true) | TransactionWithControlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | false | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | false | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (true) | ScheduleORequiredInd |
| Info In Schedule O Part V | Yes (X) | InfoInScheduleOPartVInd |
| IRP Document | 998 | IRPDocumentCnt |
| IRP Document W2 G | 24 | IRPDocumentW2GCnt |
| Backup Wthld Compliance | Yes (true) | BackupWthldComplianceInd |
| Employee | 1439 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (true) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | false | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | Yes (true) | ForeignFinancialAccountInd |
| Foreign Country | CA | ForeignCountryCd |
| Prohibited Tax Shelter Trans | false | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | false | TaxablePartyNotificationInd |
| Nondeductible Contributions | false | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | Yes (true) | QuidProQuoContributionsInd |
| Quid Pro Quo Contri Discl | Yes (true) | QuidProQuoContriDisclInd |
| Form8282 Property Disposed Of | false | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | false | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | false | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | false | IndoorTanningServicesInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 28 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 28 | IndependentVotingMemberCnt |
| Family Or Business Rln | false | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | false | DelegationOfMgmtDutiesInd |
| Change To Org Documents | Yes (true) | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | false | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | Yes (true) | MembersOrStockholdersInd |
| Election Of Board Members | Yes (true) | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | Yes (true) | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (true) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (true) | MinutesOfCommitteesInd |
| Officer Mailing Address | false | OfficerMailingAddressInd |
| Local Chapters | Yes (true) | LocalChaptersInd |
| Policies Reference Chapters | Yes (true) | PoliciesReferenceChaptersInd |
| Form990 Provided To Gvrn Body | Yes (true) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (true) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (true) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (true) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (true) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (true) | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (true) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (true) | CompensationProcessOtherInd |
| Investment In Joint Venture | false | InvestmentInJointVentureInd |
| States Where Copy Of Return Is Fld | AK | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AZ | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CO | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | DE | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | DC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | FL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | GA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | HI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | ID | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | IL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | IN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | LA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MD | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | ME | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MO | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NH | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NJ | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NM | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NE | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OH | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OK | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | PA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | PR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | RI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | SC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | TN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | UT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | VA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WV | StatesWhereCopyOfReturnIsFldCd |
| Own Website | Yes (X) | OwnWebsiteInd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | ROSEMARIE LOFFREDO | PersonNm |
| Phone | 9149495213 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1311 MAMARONECK AVENUE | AddressLine1 |
| City | WHITE PLAINS | City |
| State | NY | State |
| ZIP Code | 10605 | ZIPCode |
Form990 Part VII Section A Form990PartVIISectionAGrp (37 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt | OfficerOfficerInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd |
|---|---|---|---|---|---|---|---|---|
| JAMES A BECK | ||||||||
| BOD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| WILLIAM G BEHNKE | ||||||||
| BOD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| JORGE L BENITEZ | ||||||||
| BOD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| PETER B BROCK | ||||||||
| BOD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| A DANA CALLOW JR | ||||||||
| BOD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| SCOTT A CARROLL | ||||||||
| BOD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| ELIZABETH J CLARK | ||||||||
| BOD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| RODMAN N MYERS | ||||||||
| LIFE MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| JAMES H DAVIS PHD | ||||||||
| VICE CHAIR | 2.00 | Yes (X) | $0 | $0 | $0 | 3.00 | Yes (X) | |
| TIMOTHY DURST | ||||||||
| CHAIR | 2.00 | Yes (X) | $0 | $0 | $0 | 3.00 | Yes (X) | |
| BERNARD H GARIL | ||||||||
| BOD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| PAMELA JO HAYLOCK | ||||||||
| BOD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| RAANAN HOROWITZ | ||||||||
| BOD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| RICHARD M JEANNERET | ||||||||
| BOD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| RALPH LAWSON | ||||||||
| BOD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| JOSEPH B KELLEY | ||||||||
| BOD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| MARIE V MCDEMMOND | ||||||||
| BOD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| STEVEN T ROSENMDFACP | ||||||||
| BOD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| KENNETH M SCHWARTZ | ||||||||
| SECRETARY/TR | 2.00 | Yes (X) | $0 | $0 | $0 | 3.00 | Yes (X) | |
| KATHRYN C VECELLIO | ||||||||
| BOD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| LOUISE E WARNER | ||||||||
| BOD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| JAMES E BRADNER | ||||||||
| BOD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| BETH E HAWLEY | ||||||||
| BOD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| GILLES LEGAULT | ||||||||
| BOD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| DONALD PROCTOR | ||||||||
| BOD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| FRANK O SMITH | ||||||||
| BOD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| KEITH S WHITE | ||||||||
| BOD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| GRACIELA C ELETA | ||||||||
| BOD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| JOHN E WALTER | ||||||||
| PRES&CEO TER | 45.00 | $628,359 | $0 | $63,346 | 3.00 | Yes (X) | ||
| LOUIS J DEGENNARO | ||||||||
| PRESIDENT & | 45.00 | $446,200 | $0 | $94,307 | 3.00 | Yes (X) | ||
| JAMES T NANGLE | ||||||||
| SVP&CFO TERM | 45.00 | $408,402 | $0 | $42,373 | Yes (X) | |||
| ROSEMARIE A LOFFREDO | ||||||||
| CAO&CFO STAR | 45.00 | $136,466 | $0 | $5,319 | Yes (X) | |||
| LISA STOCKMON | ||||||||
| EVP-CHIEF MK | 45.00 | $348,455 | $0 | $35,824 | Yes (X) | |||
| GEORGE J OMIROS | ||||||||
| EVP-CHIEF CA | 45.00 | $334,718 | $0 | $45,253 | Yes (X) | |||
| MARK VELLECA | ||||||||
| CHIEF POLICY | 45.00 | $323,322 | $0 | $47,780 | Yes (X) | |||
| MARK ROITHMAYR | ||||||||
| CHIEF DEVELO | 45.00 | $320,714 | $0 | $25,806 | Yes (X) | |||
| BRIAN ROSEN | ||||||||
| CHIEF POLICY | 45.00 | $282,497 | $0 | $33,649 | Yes (X) | |||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $3,229,133 | TotalReportableCompFromOrgAmt |
| Total Other Compensation | $393,657 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 145 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | false | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (true) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | false | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (5 entries)
| Address Line1ContractorAddress/USAddress/AddressLine1 | CityContractorAddress/USAddress/City | StateContractorAddress/USAddress/State | ZIP CodeContractorAddress/USAddress/ZIPCode | ServicesServicesDesc | CompensationCompensationAmt |
|---|---|---|---|---|---|
| OLIVER STAFFING INC | |||||
| 350 LEXINGTON AV SUITE 401 | NEW YORK | NY | 10016 | TEMP STAFFING | $6,567,519 |
| PATIENT ADVOCACY FOUNDATION | |||||
| 421 BUTLER FARM RD | HAMPTON | VA | 23666 | PAT ASSIST PROC | $4,567,715 |
| MAIL AMERICA | |||||
| 174 ELKTON FARM RD | FOREST | VA | 24551 | FUNDRAISING SER | $3,745,936 |
| INFOCISION | |||||
| 325 SPRINGSIDE DRIVE | AKRON | OH | 44333 | FUNDRASING SERV | $1,728,035 |
| PARADYZ MATERA | |||||
| 5 HANOVER SQUARE | NEW YORK | NY | 10004 | FUNDRAISING SER | $1,320,036 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 54 | CntrctRcvdGreaterThan100KCnt |
| Federated Campaigns | $2,194,082 | FederatedCampaignsAmt |
| Fundraising | $163,590,328 | FundraisingAmt |
| Related Organizations | $58,002 | RelatedOrganizationsAmt |
| All Other Contributions | $136,594,740 | AllOtherContributionsAmt |
| Noncash Contributions | $890,755 | NoncashContributionsAmt |
| Total Contributions | $302,437,152 | TotalContributionsAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $1,200,545 | TotalRevenueColumnAmt |
| Exclusion | $1,200,545 | ExclusionAmt |
Royalties Revenue RoyaltiesRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $3,320 | TotalRevenueColumnAmt |
| Exclusion | $3,320 | ExclusionAmt |
Gross Amount Sales Assets GrossAmountSalesAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $90,871,363 | SecuritiesAmt |
Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $85,076,791 | SecuritiesAmt |
Gain Or Loss GainOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $5,794,572 | SecuritiesAmt |
Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $5,794,572 | TotalRevenueColumnAmt |
| Exclusion | $5,794,572 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Fundraising Gross Income | $27,272,894 | FundraisingGrossIncomeAmt |
| Contri Rpt Fundraising Event | $163,590,328 | ContriRptFundraisingEventAmt |
| Fundraising Direct Expenses | $27,272,894 | FundraisingDirectExpensesAmt |
| Gaming Gross Income | $795,990 | GamingGrossIncomeAmt |
| Gaming Direct Expenses | $240,471 | GamingDirectExpensesAmt |
Net Income From Gaming NetIncomeFromGamingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $555,519 | TotalRevenueColumnAmt |
| Exclusion | $555,519 | ExclusionAmt |
Other Revenue Misc OtherRevenueMiscGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | OTHER MISCELLANEOUS | Desc |
| Business | 900099 | BusinessCd |
| Total Revenue Column | $104,879 | TotalRevenueColumnAmt |
| Exclusion | $104,879 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Revenue Total | $104,879 | OtherRevenueTotalAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $310,095,987 | TotalRevenueColumnAmt |
| Exclusion | $7,658,835 | ExclusionAmt |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $69,785,159 | TotalAmt |
| Program Services | $69,785,159 | ProgramServicesAmt |
Grants To Domestic Individuals GrantsToDomesticIndividualsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $51,924,134 | TotalAmt |
| Program Services | $51,924,134 | ProgramServicesAmt |
Foreign Grants ForeignGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $8,540,182 | TotalAmt |
| Program Services | $8,540,182 | ProgramServicesAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $818,776 | TotalAmt |
| Program Services | $569,152 | ProgramServicesAmt |
| Management And General | $110,390 | ManagementAndGeneralAmt |
| Fundraising | $139,234 | FundraisingAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $72,881,314 | TotalAmt |
| Program Services | $50,661,660 | ProgramServicesAmt |
| Management And General | $9,826,189 | ManagementAndGeneralAmt |
| Fundraising | $12,393,465 | FundraisingAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $4,359,951 | TotalAmt |
| Program Services | $2,837,221 | ProgramServicesAmt |
| Management And General | $714,376 | ManagementAndGeneralAmt |
| Fundraising | $808,354 | FundraisingAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $11,051,482 | TotalAmt |
| Program Services | $7,191,706 | ProgramServicesAmt |
| Management And General | $1,810,781 | ManagementAndGeneralAmt |
| Fundraising | $2,048,995 | FundraisingAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $5,074,199 | TotalAmt |
| Program Services | $3,302,015 | ProgramServicesAmt |
| Management And General | $831,405 | ManagementAndGeneralAmt |
| Fundraising | $940,779 | FundraisingAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $704,547 | TotalAmt |
| Program Services | $386,222 | ProgramServicesAmt |
| Management And General | $118,487 | ManagementAndGeneralAmt |
| Fundraising | $199,838 | FundraisingAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $276,417 | TotalAmt |
| Program Services | $151,527 | ProgramServicesAmt |
| Management And General | $46,486 | ManagementAndGeneralAmt |
| Fundraising | $78,404 | FundraisingAmt |
Fees For Services Lobbying FeesForServicesLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $558,530 | TotalAmt |
| Program Services | $306,176 | ProgramServicesAmt |
| Management And General | $93,931 | ManagementAndGeneralAmt |
| Fundraising | $158,423 | FundraisingAmt |
Fees For Services Prof Fundraising FeesForServicesProfFundraising
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $7,178,370 | TotalAmt |
| Fundraising | $7,178,370 | FundraisingAmt |
Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $198,971 | TotalAmt |
| Program Services | $109,074 | ProgramServicesAmt |
| Management And General | $33,462 | ManagementAndGeneralAmt |
| Fundraising | $56,435 | FundraisingAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $17,118,168 | TotalAmt |
| Program Services | $9,383,918 | ProgramServicesAmt |
| Management And General | $2,878,834 | ManagementAndGeneralAmt |
| Fundraising | $4,855,416 | FundraisingAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $11,443,327 | TotalAmt |
| Program Services | $4,600,579 | ProgramServicesAmt |
| Management And General | $1,727,542 | ManagementAndGeneralAmt |
| Fundraising | $5,115,206 | FundraisingAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $24,283,597 | TotalAmt |
| Program Services | $10,735,405 | ProgramServicesAmt |
| Management And General | $3,515,242 | ManagementAndGeneralAmt |
| Fundraising | $10,032,950 | FundraisingAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $5,796,747 | TotalAmt |
| Program Services | $3,177,688 | ProgramServicesAmt |
| Management And General | $974,862 | ManagementAndGeneralAmt |
| Fundraising | $1,644,197 | FundraisingAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $8,442,768 | TotalAmt |
| Program Services | $5,677,843 | ProgramServicesAmt |
| Management And General | $1,330,818 | ManagementAndGeneralAmt |
| Fundraising | $1,434,107 | FundraisingAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $5,174,411 | TotalAmt |
| Program Services | $3,495,450 | ProgramServicesAmt |
| Management And General | $683,781 | ManagementAndGeneralAmt |
| Fundraising | $995,180 | FundraisingAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,874,939 | TotalAmt |
| Program Services | $2,938,562 | ProgramServicesAmt |
| Management And General | $251,127 | ManagementAndGeneralAmt |
| Fundraising | $685,250 | FundraisingAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,928,364 | TotalAmt |
| Program Services | $2,372,972 | ProgramServicesAmt |
| Management And General | $750,378 | ManagementAndGeneralAmt |
| Fundraising | $805,014 | FundraisingAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $600,054 | TotalAmt |
| Program Services | $386,432 | ProgramServicesAmt |
| Management And General | $103,072 | ManagementAndGeneralAmt |
| Fundraising | $110,550 | FundraisingAmt |
Other Expenses OtherExpensesGrp (2 entries)
| DescDesc | TotalTotalAmt | Program ServicesProgramServicesAmt | Management And GeneralManagementAndGeneralAmt | FundraisingFundraisingAmt |
|---|---|---|---|---|
| MISCELLANEOUS | $2,887,044 | $1,948,337 | $436,748 | $501,959 |
| DUES & SUBSCRIPTIONS | $296,831 | $119,335 | $44,811 | $132,685 |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $317,198,282 | TotalAmt |
| Program Services | $240,600,749 | ProgramServicesAmt |
| Management And General | $26,282,722 | ManagementAndGeneralAmt |
| Fundraising | $50,314,811 | FundraisingAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Joint Costs | Yes (X) | JointCostsInd |
Total Joint Costs TotalJointCostsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $20,809,131 | TotalAmt |
| Program Services | $8,971,856 | ProgramServicesAmt |
| Fundraising | $11,837,275 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $5,620,937 | BOYAmt |
| EOY | $6,268,949 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $19,656,020 | BOYAmt |
| EOY | $20,220,498 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $7,252,079 | BOYAmt |
| EOY | $8,575,572 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $81,719 | BOYAmt |
| EOY | $311 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $4,851,345 | BOYAmt |
| EOY | $4,955,078 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $31,199,936 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $14,790,328 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $10,594,159 | BOYAmt |
| EOY | $16,409,608 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $112,406,398 | BOYAmt |
| EOY | $125,935,503 | EOYAmt |
Investments Other Securities InvestmentsOtherSecuritiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $75,862,899 | BOYAmt |
| EOY | $60,216,008 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $236,325,556 | BOYAmt |
| EOY | $242,581,527 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $20,652,928 | BOYAmt |
| EOY | $20,275,231 | EOYAmt |
Grants Payable GrantsPayableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $80,460,957 | BOYAmt |
| EOY | $99,130,986 | EOYAmt |
Deferred Revenue DeferredRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $34,202,238 | BOYAmt |
| EOY | $26,038,202 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $135,316,123 | BOYAmt |
| EOY | $145,444,419 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows SFAS117 | Yes (X) | OrganizationFollowsSFAS117Ind |
Unrestricted Net Assets UnrestrictedNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $90,324,737 | BOYAmt |
| EOY | $67,582,758 | EOYAmt |
Temporarily Rstr Net Assets TemporarilyRstrNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $7,775,266 | BOYAmt |
| EOY | $26,592,408 | EOYAmt |
Permanently Rstr Net Assets PermanentlyRstrNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $2,909,430 | BOYAmt |
| EOY | $2,961,942 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $101,009,433 | BOYAmt |
| EOY | $97,137,108 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $236,325,556 | BOYAmt |
| EOY | $242,581,527 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part XI | Yes (X) | InfoInScheduleOPartXIInd |
| Reconcilation Revenue Expnss | -$7,102,295 | ReconcilationRevenueExpnssAmt |
| Net Unrlzd Gains Losses Invst | $6,349,371 | NetUnrlzdGainsLossesInvstAmt |
| Other Changes In Net Assets | -$3,119,401 | OtherChangesInNetAssetsAmt |
| Info In Schedule O Part XII | Yes (X) | InfoInScheduleOPartXIIInd |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | Yes (true) | AccountantCompileOrReviewInd |
| FS Audited | Yes (true) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Consolidated Basis Fincl Stmt | Yes (X) | ConsolidatedBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (true) | AuditCommitteeInd |
| Federal Grant Audit Required | false | FederalGrantAuditRequiredInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Organization170 | Yes (X) | PublicOrganization170Ind |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $238,080,823 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $270,043,865 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $282,672,072 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $279,789,664 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $302,437,152 | CurrentTaxYearAmt |
| Total | $1,373,023,576 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $238,080,823 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $270,043,865 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $282,672,072 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $279,789,664 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $302,437,152 | CurrentTaxYearAmt |
| Total | $1,373,023,576 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $194,613,347 | SubstantialContributorsTotAmt |
| Public Support Total170 | $1,178,410,229 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $4,962,639 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $3,145,637 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $2,705,046 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $2,260,636 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $1,203,865 | CurrentTaxYearAmt |
| Total | $14,277,823 | TotalAmt |
Other Income170 OtherIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $1,925,834 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $1,779,485 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $1,502,044 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $1,974,227 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $104,879 | CurrentTaxYearAmt |
| Total | $7,286,469 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $1,394,587,868 | TotalSupportAmt |
| Gross Receipts Rltd Activities | $171,720,181 | GrossReceiptsRltdActivitiesAmt |
| Public Support CY170 | 0.84500 | PublicSupportCY170Pct |
| Public Support PY170 | 0.87530 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
Form990 Schedule A Part IV Form990ScheduleAPartIVGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART II, LINE 10 | FormAndLineReferenceDesc |
| Explanation | GRANT TERMINATIONS & REFUNDS 6,966,780 OTHER MISC. REVENUE 319,689 | ExplanationTxt |
Schedule B IRS990ScheduleB
Contributor Information ContributorInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor | RESTRICTED | ContributorNum |
Contributor Business Name ContributorBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor US Address ContributorUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Contributions | RESTRICTED | TotalContributionsAmt |
Schedule C IRS990ScheduleC
| Field | Value | IRS element (for citing) |
|---|---|---|
| Volunteers | Yes (true) | VolunteersInd |
| Paid Staff Or Management | Yes (true) | PaidStaffOrManagementInd |
| Media Advertisements | false | MediaAdvertisementsInd |
| Mailings Members | false | MailingsMembersInd |
| Publications Or Broadcast | Yes (true) | PublicationsOrBroadcastInd |
| Publications Or Broadcast | $239,637 | PublicationsOrBroadcastAmt |
| Grants Other Organizations | false | GrantsOtherOrganizationsInd |
| Direct Contact Legislators | Yes (true) | DirectContactLegislatorsInd |
| Direct Contact Legislators | $786,711 | DirectContactLegislatorsAmt |
| Rallies Demonstrations | Yes (true) | RalliesDemonstrationsInd |
| Rallies Demonstrations | $90,017 | RalliesDemonstrationsAmt |
| Other Activities | Yes (true) | OtherActivitiesInd |
| Other Activities | $558,530 | OtherActivitiesAmt |
| Total Lobbying Expenditures | $1,674,895 | TotalLobbyingExpendituresAmt |
| Not Described Section501c3 | false | NotDescribedSection501c3Ind |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | SCHEDULE C, PART II-B, LINE 1 | FormAndLineReferenceDesc |
| Explanation | LLS IS A MEMBER OF A NUMBER OF COALITIONS INCLUDING FRIENDS OF CANCER RESEARCH, ALLIANCE FOR A STRONGER FDA, NATIONAL COALITION FOR CANCER RESEARCH, PATIENT ADVOCATE FOUNDATION, AMERICA ASSOCIATION FOR CANCER RESEARCH, CHILDREN'S CAUSE FOR CANCER ADVOCACY, THE CANCER LEADERSHIP COUNCIL AND THE ANTICANCER AGENT DEVELOPMENT AND VALIDATION WORKSHOP. LLS PARTNERS WITH A NUMBER OF LOBBYING FIRMS WHO WORK WITH OUR PUBLIC POLICY STAFF TO CARRY OUT OUR LOBBYING OBJECTIVES. LLS MOBILIZES PATIENT-ADVOCATES AND VOLUNTEERS TO ENGAGE WITH THEIR FEDERAL AND STATE LEGISLATORS THROUGH DIGITAL ADVOCACY - SENDING LETTERS; SHARING THEIR PERSONAL STORIES; SIGNING PETITIONS; AND ENCOURAGING THEIR LEGISLATORS TO SUPPORT LLS' POLICY PRIORITIES. IN CONJUNCTION WITH LLS EMPLOYEES, PATIENT-ADVOCATES ALSO VISIT THEIR LEGISLATORS IN THEIR LOCAL OFFICES, IN WASHINGTON, DC AND IN STATE CAPITOLS TO FURTHER LLS' POLICY AGENDA. | ExplanationTxt |
Schedule D IRS990ScheduleD
| Field | Value | IRS element (for citing) |
|---|---|---|
| Collection Used Pub Exhibition | Yes (X) | CollectionUsedPubExhibitionInd |
| Solicited Assets Sale | false | SolicitedAssetsSaleInd |
CY Endwmt Fund CYEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $6,027,657 | BeginningYearBalanceAmt |
| Investment Earnings Or Losses | $313,872 | InvestmentEarningsOrLossesAmt |
| Grants Or Scholarships | -$215,000 | GrantsOrScholarshipsAmt |
| Administrative Expenses | -$3,831 | AdministrativeExpensesAmt |
| End Year Balance | $6,122,698 | EndYearBalanceAmt |
CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $6,000,186 | BeginningYearBalanceAmt |
| Investment Earnings Or Losses | $482,520 | InvestmentEarningsOrLossesAmt |
| Grants Or Scholarships | -$450,000 | GrantsOrScholarshipsAmt |
| Administrative Expenses | -$5,049 | AdministrativeExpensesAmt |
| End Year Balance | $6,027,657 | EndYearBalanceAmt |
CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $6,059,994 | BeginningYearBalanceAmt |
| Investment Earnings Or Losses | $48,916 | InvestmentEarningsOrLossesAmt |
| Administrative Expenses | -$9,992 | AdministrativeExpensesAmt |
| End Year Balance | $6,000,186 | EndYearBalanceAmt |
CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $5,023,902 | BeginningYearBalanceAmt |
| Contributions | $111,064 | ContributionsAmt |
| Investment Earnings Or Losses | $938,068 | InvestmentEarningsOrLossesAmt |
| Administrative Expenses | -$13,040 | AdministrativeExpensesAmt |
| End Year Balance | $6,059,994 | EndYearBalanceAmt |
CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $4,481,610 | BeginningYearBalanceAmt |
| Investment Earnings Or Losses | $563,236 | InvestmentEarningsOrLossesAmt |
| Administrative Expenses | -$20,944 | AdministrativeExpensesAmt |
| End Year Balance | $5,023,902 | EndYearBalanceAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Prmnnt Endowment Balance EOY | 0.48000 | PrmnntEndowmentBalanceEOYPct |
| Term Endowment Balance EOY | 0.52000 | TermEndowmentBalanceEOYPct |
| Endowments Held Unrelated Org | false | EndowmentsHeldUnrelatedOrgInd |
| Endowments Held Related Org | false | EndowmentsHeldRelatedOrgInd |
Leasehold Improvements LeaseholdImprovementsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $953,362 | OtherCostOrOtherBasisAmt |
| Depreciation | $434,856 | DepreciationAmt |
| Book Value | $518,506 | BookValueAmt |
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $27,556,719 | OtherCostOrOtherBasisAmt |
| Depreciation | $11,922,469 | DepreciationAmt |
| Book Value | $15,634,250 | BookValueAmt |
Other Land Buildings OtherLandBuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $2,689,855 | OtherCostOrOtherBasisAmt |
| Depreciation | $2,433,003 | DepreciationAmt |
| Book Value | $256,852 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $16,409,608 | TotalBookValueLandBuildingsAmt |
Other Securities OtherSecuritiesGrp (5 entries)
| DescDesc | Book ValueBookValueAmt | Method ValuationMethodValuationCd |
|---|---|---|
| FUND OF HEDGE FUNDS- OPERATING | $54,020,325 | F |
| LIMITED PARTNERSHIP EQUITIES-OPERATI | $2,597,869 | F |
| FUND OF HEDGE FUNDS-ENDOWMENT | $1,653,526 | F |
| 457B PLAN | $1,648,380 | F |
| LIMITED PARTNERSHIP EQUITIES-ENDOWME | $295,908 | F |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Securities | $60,216,008 | TotalBookValueSecuritiesAmt |
| Footnote Text | Yes (X) | FootnoteTextInd |
| Total Rev Etc Audited Fincl Stmt | $339,832,605 | TotalRevEtcAuditedFinclStmtAmt |
| Net Unrealized Gains Invst | $6,349,371 | NetUnrealizedGainsInvstAmt |
| Donated Services And Use Fclts | $10,982,172 | DonatedServicesAndUseFcltsAmt |
| Other Revenue | $12,662,047 | OtherRevenueAmt |
| Revenue Not Reported | $29,993,590 | RevenueNotReportedAmt |
| Revenue Subtotal | $309,839,015 | RevenueSubtotalAmt |
| Investment Expenses Not Incld | $198,971 | InvestmentExpensesNotIncldAmt |
| Other Revenues Not Included | $58,001 | OtherRevenuesNotIncludedAmt |
| Revenue Not Reported Fincl Stmt | $256,972 | RevenueNotReportedFinclStmtAmt |
| Total Revenue Per Form990 | $310,095,987 | TotalRevenuePerForm990Amt |
| Tot Expns Etc Audited Fincl Stmt | $343,191,816 | TotExpnsEtcAuditedFinclStmtAmt |
| Donated Services Use Fclts | $10,982,172 | DonatedServicesUseFcltsAmt |
| Other Expenses Included | $15,210,333 | OtherExpensesIncludedAmt |
| Expenses Not Reported | $26,192,505 | ExpensesNotReportedAmt |
| Expenses Subtotal | $316,999,311 | ExpensesSubtotalAmt |
| Investment Expenses Not Incld2 | $198,971 | InvestmentExpensesNotIncld2Amt |
| Expenses Not Rpt Fincl Stmt | $198,971 | ExpensesNotRptFinclStmtAmt |
| Total Expenses Per Form990 | $317,198,282 | TotalExpensesPerForm990Amt |
Supplemental Information Detail SupplementalInformationDetail (7 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| SCHEDULE D, PAGE 2, PART III, LINE 4 | THE LLS COLLECTION IS OF PHOTOGRAPHS WHICH ARE USED FOR PUBLIC EXHIBITION AT FUNDRAISING EVENTS HELD TO SUPPORT LLS'S PROGRAMS. |
| SCHEDULE D, PAGE 2, PART V, LINE 4 | LLS'S ENDOWMENTS ARE INTENDED TO FUND RESEARCH AS WELL AS SUPPORT LLS'S PUBLIC EDUCATION PROGRAMS. |
| SCHEDULE D, PAGE 3, PART X | LLS RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE TAX POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. INCOME GENERATED FROM ACTIVITIES UNRELATED TO LLS'S EXEMPT PURPOSE IS SUBJECT TO TAX UNDER INTERNAL REVENE CODE SECTION 511. LLS DID NOT RECOGNIZE ANY UNRELATED BUSINESS INCOME TAX LIABILITY FOR THE YEARS ENDED JUNE 30, 2014 AND 2013. |
| SCHEDULE D, PAGE 4, PART XI, LINE 2D | LLS CANADA REVENUE 12,662,047 |
| SCHEDULE D, PAGE 4, PART XI, LINE 4B | LSRP CONTRIBUTION 58,002 ROUNDING -1 |
| SCHEDULE D, PAGE 4, PART XII, LINE 2D | LLS CANADA EXPENSES 11,853,901 FOREIGN CURRENCY TRANSALATION ADJUSTMENT 153,433 ROUNDING -4 WRITE-OFF OF CONTRIBUTIONS RECEIVABLE 3,507,289 GRANT REFUND EXPENSED IN PRIOR YEAR -304,286 |
| SCHEDULE D, PAGE 4, PART XIII | LLS MAINTAINS A SMALL PHOTOGRAPH COLLECTION FOR PUBLIC EXHIBITION WHICH HAS AN ESTIMATED VALUE OF BETWEEN 20,000 AND 50,000. AS THIS REPRESENTS A RELATIVELY SMALL PERCENTAGE OF LLS'S ASSETS, IT IS NOT SEPARATELY DISCLOSED IN THE FINANCIAL STATEMENTS OR FOOTNOTES. |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (true) | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp (4 entries)
| RegionRegionTxt | EmployeeEmployeeCnt | Type Of Activities ConductedTypeOfActivitiesConductedTxt | Specific Services ProvidedSpecificServicesProvidedTxt | Region Total ExpendituresRegionTotalExpendituresAmt | OfficesOfficesCnt |
|---|---|---|---|---|---|
| EAST ASIA | 4 | RESEARCH FUNDING | RESEARCH GRANTS | $1,548,714 | |
| EUROPE | 13 | RESEARCH FUNDING | RESEARCH GRANTS | $4,389,865 | |
| NORTH AMERICA | 13 | RESEARCH FUNDING | RESEARCH GRANTS | $2,601,603 | 7 |
| CENTRAL AMERICA & CARIBBEAN | INVESTMENTS | INVESTMENTS | $25,156,350 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Offices | 7 | SubtotalOfficesCnt |
| Subtotal Employees | 30 | SubtotalEmployeesCnt |
| Total Office | 7 | TotalOfficeCnt |
| Total Employee | 30 | TotalEmployeeCnt |
| Subtotal Spent | $33,696,532 | SubtotalSpentAmt |
| Total Spent | $33,696,532 | TotalSpentAmt |
Grants To Org Outside US GrantsToOrgOutsideUSGrp (25 entries)
| RegionRegionTxt | Purpose Of GrantPurposeOfGrantTxt | Cash GrantCashGrantAmt | Manner Of Cash DisbursementMannerOfCashDisbursementTxt | Valuation Method UsedValuationMethodUsedDesc |
|---|---|---|---|---|
| EAST ASIA & PACIFIC | RESEARCH GRANT | $55,000 | CHECK | ACCRUAL |
| EAST ASIA & PACIFIC | RESEARCH GRANT | $1,250,000 | CHECK | ACCRUAL |
| EAST ASIA & PACIFIC | RESEARCH GRANT | $200,000 | CHECK | ACCRUAL |
| EAST ASIA & PACIFIC | THERAPY ACCELERATION | $43,713 | CHECK | FMV |
| EUROPE | RESEARCH GRANT | $110,000 | WIRE | ACCRUAL |
| EUROPE | RESEARCH GRANT | $110,000 | WIRE | ACCRUAL |
| EUROPE | RESEARCH GRANT | $1,250,000 | CHECK | ACCRUAL |
| EUROPE | RESEARCH GRANT | $398,748 | CHECK | ACCRUAL |
| EUROPE | THERAPY ACCELERATION | $750,000 | CHECK | FMV |
| EUROPE | THERAPY ACCELERATION | $750,000 | CHECK | FMV |
| EUROPE | THERAPY ACCELERATION | $9,554 | CHECK | FMV |
| EUROPE | THERAPY ACCELERATION | $1,000,000 | CHECK | FMV |
| EUROPE | THERAPY ACCELERATION | $11,563 | CHECK | FMV |
| NORTH AMERICA | RESEARCH GRANT | $200,000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | $200,000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | $200,000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | $200,000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | $200,000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | $505,999 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | $200,000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | $200,000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | $300,000 | CHECK | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | $363,353 | CHECK | ACCRUAL |
| NORTH AMERICA | THERAPY ACCELERATION | $25,338 | CHECK | FMV |
| NORTH AMERICA | THERAPY ACCELERATION | $5,132 | CHECK | FMV |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Org | 20 | TotalOtherOrgCnt |
| Transfer To Foreign Corp | Yes (true) | TransferToForeignCorpInd |
| Interest In Foreign Trust | false | InterestInForeignTrustInd |
| Foreign Corp Ownership | Yes (true) | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | Yes (true) | PassiveForeignInvestmestCoInd |
| Foreign Partnership | false | ForeignPartnershipInd |
| Boycott Countries | false | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| SCHEDULE F, PAGE 1, PART I, LINE 2 | FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS,EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. |
| SCHEDULE F, PAGE 1, PART I, LINE 3 | EAST ASIA 1,548,714 0 EUROPE 4,389,865 0 NORTH AMERICA 2,601,603 0 CENTRAL AMERICA & CARIBBEAN 0 25,156,350 |
Schedule G IRS990ScheduleG
| Field | Value | IRS element (for citing) |
|---|---|---|
| Mail Solicitations | Yes (X) | MailSolicitationsInd |
| Email Solicitations | Yes (X) | EmailSolicitationsInd |
| Phone Solicitations | Yes (X) | PhoneSolicitationsInd |
| In Person Solicitations | Yes (X) | InPersonSolicitationsInd |
| Solicitation Of Non Govt Grants | Yes (X) | SolicitationOfNonGovtGrantsInd |
| Solicitation Of Govt Grants | Yes (X) | SolicitationOfGovtGrantsInd |
| Special Fundraising Events | Yes (X) | SpecialFundraisingEventsInd |
| Agrmt Prof Fundraising Acty | Yes (true) | AgrmtProfFundraisingActyInd |
Fundraiser Activity Info FundraiserActivityInfoGrp (8 entries)
| Address Line1USAddress/AddressLine1 | CityUSAddress/City | StateUSAddress/State | ZIP CodeUSAddress/ZIPCode | ActivityActivityTxt | Fundraiser Control Of FundsFundraiserControlOfFundsInd | Retained By ContractorRetainedByContractorAmt | Net To OrganizationNetToOrganizationAmt |
|---|---|---|---|---|---|---|---|
| MAIL AMERICA COMMUNICATIONS INC | |||||||
| 174 ELKTON FARM ROAD | FOREST | VA | 24551 | DIRECT MAI | false | $3,745,937 | -$3,745,937 |
| INFOCISION | |||||||
| 325 SPRINSIDE DRIVE | AKRON | OH | 44333 | TELEMARKET | false | $1,728,035 | -$1,728,035 |
| PARADYZ MATERA | |||||||
| 5 HANOVER SQUARE 6TH FLOOR | NEW YORK | NY | 10004 | DIRECT MAI | false | $1,320,036 | -$1,320,036 |
| EPSILON | |||||||
| DALLAS 6021 CONNECTION DR | IRVING | TX | 75039 | DIRECT MAI | false | $1,259,581 | -$1,259,581 |
| DIRECT PRINT COMMUNICATIONS | |||||||
| 201 EAST SANDPOINTE SUITE 400 | SANTA ANA | CA | 92707 | DIRECT MAI | false | $991,528 | -$991,528 |
| THOMPSON HABIB & DENISON | |||||||
| 80 HAYDEN AVENUE SUITE 300 | LEXINGTON | MA | 02421 | DIRECT MAI | false | $672,496 | -$672,496 |
| DONOR CARE CENTER INC | |||||||
| 4345 STRAUSSSER ST NW | NOTH CANTON | OH | 44720 | TELEMARKET | false | $245,058 | -$245,058 |
| BLACKBAUD | |||||||
| 1800 DIAGONAL ROAD SUITE 400 | ALEXANDRIA | VA | 22314 | DIRECT MAI | false | $101,502 | -$101,502 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Retained By Contractors | $10,064,173 | TotalRetainedByContractorsAmt |
| Total Net To Organization | -$10,064,173 | TotalNetToOrganizationAmt |
| All States | All States | AllStatesCd |
Fundraising Event Information FundraisingEventInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Name Of Event1 | NIKE WOMEN HALF | NameOfEvent1Amt |
| Gross Receipts Event1 | $4,339,846 | GrossReceiptsEvent1Amt |
| Charitable Contri Event1 | $3,606,608 | CharitableContriEvent1Amt |
| Gross Revenue Event1 | $733,238 | GrossRevenueEvent1Amt |
| Other Direct Expenses Event1 | $733,238 | OtherDirectExpensesEvent1Amt |
| Name Of Event2 | NIKE WOMENS MAR | NameOfEvent2Amt |
| Gross Receipts Event2 | $8,884,317 | GrossReceiptsEvent2Amt |
| Charitable Contri Event2 | $6,946,142 | CharitableContriEvent2Amt |
| Gross Revenue Event2 | $1,938,175 | GrossRevenueEvent2Amt |
| Other Direct Expenses Event2 | $1,938,175 | OtherDirectExpensesEvent2Amt |
| Other Events Total | 1027 | OtherEventsTotalCnt |
| Gross Receipts Other Events | $177,639,059 | GrossReceiptsOtherEventsAmt |
| Charitable Contri Other Events | $153,037,578 | CharitableContriOtherEventsAmt |
| Gross Revenue Other Events | $24,601,481 | GrossRevenueOtherEventsAmt |
| Oth Direct Expnss Other Events | $24,601,481 | OthDirectExpnssOtherEventsAmt |
| Gross Receipts Total | $190,863,222 | GrossReceiptsTotalAmt |
| Charitable Contributions Tot | $163,590,328 | CharitableContributionsTotAmt |
| Gross Revenue Total Events | $27,272,894 | GrossRevenueTotalEventsAmt |
| Oth Direct Expnss Total Events | $27,272,894 | OthDirectExpnssTotalEventsAmt |
| Direct Expense Summary Events | $27,272,894 | DirectExpenseSummaryEventsAmt |
Gaming Information GamingInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Volunteer Labor Bingo | false | VolunteerLaborBingoInd |
| Volunteer Labor Pull Tabs | false | VolunteerLaborPullTabsInd |
| Gross Revenue Other Gaming | $795,990 | GrossRevenueOtherGamingAmt |
| Cash Prizes Other Gaming | $7,653 | CashPrizesOtherGamingAmt |
| Non Cash Prizes Other Gaming | $230,067 | NonCashPrizesOtherGamingAmt |
| Oth Direct Expnss Other Gaming | $2,751 | OthDirectExpnssOtherGamingAmt |
| Volunteer Labor Other Gaming | Yes (true) | VolunteerLaborOtherGamingInd |
| Volunteer Labor Other Gaming | 0.71000 | VolunteerLaborOtherGamingPct |
| Gross Revenue Total Gaming | $795,990 | GrossRevenueTotalGamingAmt |
| Cash Prizes Total Gaming | $7,653 | CashPrizesTotalGamingAmt |
| Non Cash Prizes Total Gaming | $230,067 | NonCashPrizesTotalGamingAmt |
| Oth Direct Expnss Total Gaming | $2,751 | OthDirectExpnssTotalGamingAmt |
| Direct Expense Summary Gaming | $240,471 | DirectExpenseSummaryGamingAmt |
| Net Gaming Income Summary | $555,519 | NetGamingIncomeSummaryAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Licensed | Yes (true) | LicensedInd |
| License Suspended Etc | false | LicenseSuspendedEtcInd |
| Gaming With Nonmembers | false | GamingWithNonmembersInd |
| Member Of Other Entity | false | MemberOfOtherEntityInd |
| Gaming Own Facility | 0.25000 | GamingOwnFacilityPct |
| Gaming Other Facility | 0.75000 | GamingOtherFacilityPct |
| Individual With Books | ROSEMARIE LOFFREDO | IndividualWithBooksNm |
Persons With Books US Address PersonsWithBooksUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1311 MAMARONECK AVENUE | AddressLine1 |
| City | WHITE PLAINS | City |
| State | NY | State |
| ZIP Code | 10605 | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct With3rd Prty For Game Rev | false | CntrctWith3rdPrtyForGameRevInd |
| Gaming Manager Person | SEE SCHEDULE G PART IV | GamingManagerPersonNm |
| Charitable Distribution Rqr | false | CharitableDistributionRqrInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | SCHEDULE G, PART IV | FormAndLineReferenceDesc |
| Explanation | SCHEDULE G PART I, LINE 2B LLS USED INFOCISION, MAIL AMERICA COMMUNICATIONS, DONOR CARE CENTER INC., EPSILON AND THOMPSON, HABIB & DENISON FOR ITS NATIONAL COMMUNITY CAMPAIGN AND DIRECT MAIL PROGRAMS. THESE PROGRAMS GENERATED GROSS RECEIPTS OF 19,483,579 DURING FISCAL YEAR 2014. LLS USED DIRECT PRINT COMMUNICATIONS, PARADYZ MATERA AND BLACKBAUD FOR ALL OF ITS OTHER FUNDRAISING EVENTS DURING FISCAL YEAR 2014. SCHEDULE G, PART III, LINE 9 - STATES WITH GAMING OPERATIONS ARIZONA, DISTRICT OF COLUMBIA, IOWA, KANSAS, LOUISIANA, MICHIGAN, NEVADA, NEW YORK, OHIO, OREGON, PENNSYLVANIA, RHODE ISLAND, TEXAS, WISCONSIN. SCHEDULE G, PART III, LINE 16 THE LEUKEMIA & LYMPHOMA SOCIETY DOES NOT HAVE AN OVERALL MANAGER FOR GAMING ACTIVITIES. EACH GAMING EVENT IS MANAGED LOCALLY BY THE SPECIFIC CHAPTER STAFF. | ExplanationTxt |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (true) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (364 entries)
| Address Line1USAddress/AddressLine1 | CityUSAddress/City | StateUSAddress/State | ZIP CodeUSAddress/ZIPCode | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc | Cash GrantCashGrantAmt | Valuation Method UsedValuationMethodUsedDesc | Purpose Of GrantPurposeOfGrantTxt |
|---|---|---|---|---|---|---|---|---|
| ALBERT EINSTEIN COLLEGE OF MEDICINE | ||||||||
| 1300 MORRIS PARK AVE | BRONX | NY | 10461 | 131624225 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| ALBERT EINSTEIN COLLEGE OF MEDICINE | ||||||||
| 1300 MORRIS PARK AVE | BRONX | NY | 10461 | 131624225 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| ALBERT EINSTEIN COLLEGE OF MEDICINE | ||||||||
| 1300 MORRIS PARK AVE | BRONX | NY | 10461 | 131624225 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| ALBERT EINSTEIN COLLEGE OF MEDICINE | ||||||||
| 1300 MORRIS PARK AVE | BRONX | NY | 10461 | 131624225 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| ALBERT EINSTEIN COLLEGE OF MEDICINE | ||||||||
| 1300 MORRIS PARK AVE | BRONX | NY | 10461 | 131624225 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| BAYLOR COLLEGE OF MEDICINE | ||||||||
| 1 BAYLOR PLAZA | HOUSTON | TX | 77030 | 741613878 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| BAYLOR COLLEGE OF MEDICINE | ||||||||
| 1 BAYLOR PLAZA | HOUSTON | TX | 77030 | 741613878 | 3 | $1,250,000 | ACCRUAL | RESEARCH GRANT |
| BECKMAN RESEARCH INSTITUTE OF THE C | ||||||||
| 1500 EAST DUARTE RD | DUARTE | CA | 91010 | 953432210 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| BECKMAN RESEARCH INSTITUTE OF THE C | ||||||||
| 1500 EAST DUARTE RD | DUARTE | CA | 91010 | 953432210 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| BECKMAN RESEARCH INSTITUTE OF THE C | ||||||||
| 1500 EAST DUARTE RD | DUARTE | CA | 91010 | 953432210 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| BETH ISRAEL DEACONESS MEDICAL CENTE | ||||||||
| 330 BROOKLINE AVENUE | BOSTON | MA | 02215 | 042103881 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| BETH ISRAEL DEACONESS MEDICAL CENTE | ||||||||
| 330 BROOKLINE AVENUE | BOSTON | MA | 02215 | 042103881 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| BETH ISRAEL DEACONESS MEDICAL CENTE | ||||||||
| 330 BROOKLINE AVENUE | BOSTON | MA | 02215 | 042103881 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| BOARD OF REGENTS OF THE UNIVERSITY | ||||||||
| 4400 EMILE ST | OMAHA | NE | 68198 | 470049123 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| BRANDEIS UNIVERSITY | ||||||||
| 415 SOUTH ST | WALTHAM | MA | 02453 | 042103552 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| BRIGHAM AND WOMEN'S HOSPITAL INC | ||||||||
| 75 FRANCIS STREET | BOSTON | MA | 02115 | 042312909 | 3 | $190,657 | ACCRUAL | RESEARCH GRANT |
| BRIGHAM AND WOMEN'S HOSPITAL INC | ||||||||
| 75 FRANCIS STREET | BOSTON | MA | 02115 | 042312909 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| BRIGHAM AND WOMEN'S HOSPITAL INC | ||||||||
| 75 FRANCIS STREET | BOSTON | MA | 02115 | 042312909 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| BRIGHAM AND WOMEN'S HOSPITAL INC | ||||||||
| 75 FRANCIS STREET | BOSTON | MA | 02115 | 042312909 | 3 | $1,250,000 | ACCRUAL | RESEARCH GRANT |
| STANFORD UNIVERSITY MEDICAL CENTER | ||||||||
| 291 CAMPUS DR | STANFORD | CA | 94305 | 941156365 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| STANFORD UNIVERSITY MEDICAL CENTER | ||||||||
| 291 CAMPUS DR | STANFORD | CA | 94305 | 941156365 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| STANFORD UNIVERSITY MEDICAL CENTER | ||||||||
| 291 CAMPUS DR | STANFORD | CA | 94305 | 941156365 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 500 PARNASSUS AVE | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| CA INSTITUTE OF TECHNOLOGY | ||||||||
| 1200 E CALIFORNIA BLVD | PASADENA | CA | 91125 | 951643307 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| CA INSTITUTE OF TECHNOLOGY | ||||||||
| 1200 E CALIFORNIA BLVD | PASADENA | CA | 91125 | 951643307 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| CASE WESTERN RESERVE UNIVERSITY - S | ||||||||
| 2109 ADELBERT RD | CLEVELAND | OH | 44106 | 341018992 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| CHILDREN'S HOSPITAL BOSTON | ||||||||
| 300 LONGWOOD AVE | BOSTON | MA | 02115 | 042774441 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| CHILDREN'S HOSPITAL BOSTON | ||||||||
| 300 LONGWOOD AVE | BOSTON | MA | 02115 | 042774441 | 3 | $1,329,926 | ACCRUAL | RESEARCH GRANT |
| CHILDREN'S HOSPITAL BOSTON | ||||||||
| 300 LONGWOOD AVE | BOSTON | MA | 02115 | 042774441 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| CHILDREN'S HOSPITAL BOSTON | ||||||||
| 300 LONGWOOD AVE | BOSTON | MA | 02115 | 042774441 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| CHILDREN'S HOSPITAL BOSTON | ||||||||
| 300 LONGWOOD AVE | BOSTON | MA | 02115 | 042774441 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| CHILDREN'S HOSPITAL BOSTON AND HARV | ||||||||
| 300 LONGWOOD AVE | BOSTON | MA | 02115 | 042774441 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| CHILDRENS HOSPITAL LOS ANGELES | ||||||||
| 4650 SUNSET BLVD | LOS ANGELES | CA | 90027 | 951690977 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| CHILDRENS HOSPITAL MEDICAL CENTER-C | ||||||||
| 3333 BURNET AVE | CINCINNATI | OH | 45229 | 310833936 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| CHILDRENS HOSPITAL MEDICAL CENTER-C | ||||||||
| 3333 BURNET AVE | CINCINNATI | OH | 45229 | 310833936 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| CHILDREN'S HOSPITAL PHILADELPHIA | ||||||||
| 34TH STREET AND CIVIC CENTER BOULE | PHILADELPHIA | PA | 19104 | 231352166 | 3 | $400,000 | ACCRUAL | RESEARCH GRANT |
| CINCINNATI CHILDREN'S HOSPITAL MEDI | ||||||||
| 3333 BURNET AVE | CINCINNATI | OH | 45229 | 310833936 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| CINCINNATI CHILDREN'S HOSPITAL MEDI | ||||||||
| 3333 BURNET AVE | CINCINNATI | OH | 45229 | 310833936 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| CLEVELAND CLINIC FOUNDATION | ||||||||
| 9200 EUCLID AVE | CLEVELAND | OH | 44195 | 912153073 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| CLEVELAND CLINIC FOUNDATION | ||||||||
| 9200 EUCLID AVE | CLEVELAND | OH | 44195 | 912153073 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| COLUMBIA UNIVERSITY | ||||||||
| 116TH ST BROADWAY | NEW YORK | NY | 10027 | 135598093 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| COLUMBIA UNIVERSITY | ||||||||
| 615 WEST 131 STREET | NEW YORK | NY | 10027 | 135598093 | 3 | $400,000 | ACCRUAL | RESEARCH GRANT |
| COLUMBIA UNIVERSITY MEDICAL CENTER | ||||||||
| 630 W 168TH STREET | NEW YORK | NY | 10032 | 135598093 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| COLUMBIA UNIVERSITY MEDICAL CENTER | ||||||||
| 630 W 168TH STREET | NEW YORK | NY | 10032 | 135598093 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| COLUMBIA UNIVERSITY MEDICAL CENTER | ||||||||
| 630 W 168TH STREET | NEW YORK | NY | 10032 | 135598093 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| COLUMBIA UNIVERSITY MEDICAL CENTER | ||||||||
| 630 W 168TH STREET | NEW YORK | NY | 10032 | 135598093 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| COLUMBIA UNIVERSITY MEDICAL CENTER | ||||||||
| 630 W 168TH STREET | NEW YORK | NY | 10032 | 135598093 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| COLUMBIA UNIVERSITY MEDICAL CENTER | ||||||||
| 630 W 168TH STREET | NEW YORK | NY | 10032 | 135598093 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| COLUMBIA UNIVERSITY MEDICAL CENTER | ||||||||
| 630 W 168TH STREET | NEW YORK | NY | 10032 | 135598093 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| COLUMBIA UNIVERSITY MEDICAL CENTER | ||||||||
| 630 W 168TH STREET | NEW YORK | NY | 10032 | 135598093 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| COLUMBIA UNIVERSITY MEDICAL CENTER | ||||||||
| 630 W 168TH STREET | NEW YORK | NY | 10032 | 135598093 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| DANA FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| DANA FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| DANA FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $136,590 | ACCRUAL | RESEARCH GRANT |
| DANA FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $288,910 | ACCRUAL | RESEARCH GRANT |
| DANA FARBER CANCER INSTITUTE THE J | ||||||||
| 10 BROOKLINE PLACE WEST | BROOKLINE | MA | 02445 | 042263040 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| DANA FARBER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $194,425 | FMV | THERAPY ACCELERATION |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $1,250,000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $37,500 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVE | BOSTON | MA | 02215 | 042263040 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVENUE | BOSTON | MA | 02215 | 042263040 | 3 | $400,000 | ACCRUAL | RESEARCH GRANT |
| DUKE UNIVERSITY MEDICAL CENTER | ||||||||
| 324 BLACKWELL STREET | DURHAM | NC | 27708 | 560532129 | 3 | $382,081 | ACCRUAL | RESEARCH GRANT |
| EMORY UNIVERSITY | ||||||||
| 201 DOWMAN DR | ATLANTA | GA | 30322 | 580566256 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| EMORY UNIVERSITY | ||||||||
| PO BOX 935084 | ALTANTA | GA | 31193 | 580566256 | 3 | $450,000 | FMV | THERAPY ACCELERATION |
| FOX CHASE CANCER CENTER | ||||||||
| 333 COTTMAN AVE | PHILADELPHIA | PA | 19111 | 232003072 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| FRED HUTCHINSON CANCER RESEARCH CEN | ||||||||
| 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | 237156071 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| FRED HUTCHINSON CANCER RESEARCH CEN | ||||||||
| 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | 237156071 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| FRED HUTCHINSON CANCER RESEARCH CEN | ||||||||
| 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | 237156071 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| FRED HUTCHINSON CANCER RESEARCH CEN | ||||||||
| 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | 237156071 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| FRED HUTCHINSON CANCER RESEARCH CEN | ||||||||
| 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | 237156071 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| FRED HUTCHINSON CANCER RESEARCH CEN | ||||||||
| 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | 237156071 | 3 | $100,000 | ACCRUAL | RESEARCH GRANT |
| FRED HUTCHINSON CANCER RESEARCH CEN | ||||||||
| 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | 237156071 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| GEORGIA CENTER FOR ONCOLOGY RESEARC | ||||||||
| 50 HURT PLAZA | ALTANTA | GA | 30303 | 571159979 | 3 | $190,494 | FMV | THERAPY ACCELERATION |
| H LEE MOFFITT CANCER CENTER & RESE | ||||||||
| 12902 USF MAGNOLIA DR | TAMPA | FL | 33612 | 593238636 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| HARVARD MEDICAL SCHOOL | ||||||||
| 25 SHATTUCK ST | BOSTON | MA | 02115 | 042103580 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| HARVARD MEDICAL SCHOOL | ||||||||
| 25 SHATTUCK ST | BOSTON | MA | 02115 | 042103580 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| HARVARD MEDICAL SCHOOL | ||||||||
| 25 SHATTUCK ST | BOSTON | MA | 02115 | 042103580 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| HARVARD MEDICAL SCHOOL | ||||||||
| 25 SHATTUCK ST | BOSTON | MA | 02115 | 042103580 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| ICAHN SCHOOL OF MEDICINE AT MOUNT S | ||||||||
| 1428 MADISON AVE | NEW YORK | NY | 10029 | 136171197 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| IMMUNE DISEASE INSTITUTE (FKA) THE | ||||||||
| 3 BLACKFAN CIR | BOSTON | MA | 02115 | 042103580 | 3 | $1,250,000 | ACCRUAL | RESEARCH GRANT |
| INDIANA UNIVERSITY | ||||||||
| 420 UNIVERSITY BLVD | INDIANAPOLIS | IN | 46202 | 356001673 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| JOAN & SANFORD I WEILL CORNELL MED | ||||||||
| 1300 YORK AVE | NEW YORK | NY | 10065 | 131623978 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| JOAN & SANFORD I WEILL MEDICAL COL | ||||||||
| 1300 YORK AVE | NEW YORK | NY | 10065 | 131623978 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| JOAN & SANFORD I WEILL MEDICAL COL | ||||||||
| 1300 YORK AVE | NEW YORK | NY | 10065 | 131623978 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| JOAN & SANFORD I WEILL MEDICAL COL | ||||||||
| 1300 YORK AVE | NEW YORK | NY | 10065 | 131623978 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| JOAN & SANFORD I WEILL MEDICAL COL | ||||||||
| 1300 YORK AVE | NEW YORK | NY | 10065 | 131623978 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| JOAN & SANFORD I WEILL MEDICAL COL | ||||||||
| 1300 YORK AVE | NEW YORK | NY | 10065 | 131623978 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| JOAN & SANFORD I WEILL MEDICAL COL | ||||||||
| 1300 YORK AVE | NEW YORK | NY | 10065 | 131623978 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| JOAN & SANFORD I WEILL MEDICAL COL | ||||||||
| 1300 YORK AVE | NEW YORK | NY | 10065 | 131623978 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| JOAN & SANFORD I WEILL MEDICAL COL | ||||||||
| 1300 YORK AVE | NEW YORK | NY | 10065 | 131623978 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| JOAN & SANFORD I WEILL MEDICAL COL | ||||||||
| 1300 YORK AVE | NEW YORK | NY | 10065 | 131623978 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| JOHNS HOPKINS UNIVERSITY | ||||||||
| 733 NORTH BROADWAY | BALTIMORE | MD | 21205 | 520595110 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| JOHNS HOPKINS UNIVERSITY | ||||||||
| 733 NORTH BROADWAY | BALTIMORE | MD | 21205 | 520595110 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| JOHNS HOPKINS UNIVERSITY | ||||||||
| 733 NORTH BROADWAY | BALTIMORE | MD | 21205 | 520595110 | 3 | $277,750 | ACCRUAL | RESEARCH GRANT |
| JOHNS HOPKINS UNIVERSITY CENTR | ||||||||
| 12529 COLLECTIONS CENTER DRIVE | CHICAGO | IL | 60693 | 520595110 | 3 | $350,000 | FMV | THERAPY ACCELERATION |
| JOHNS HOPKINS UNIVERSITY CENTR | ||||||||
| 12529 COLLECTIONS CENTER DRIVE | CHICAGO | IL | 60693 | 520595110 | 3 | $700,000 | FMV | THERAPY ACCELERATION |
| JOHNS HOPKINS UNIVERSITY SCHOOL OF | ||||||||
| 733 N BROADWAY | BALTIMORE | MD | 21205 | 520595110 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| JOHNS HOPKINS UNIVERSITY SCHOOL OF | ||||||||
| 733 N BROADWAY | BALTIMORE | MD | 21205 | 520595110 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| JOHNS HOPKINS UNIVERSITY SCHOOL OF | ||||||||
| 733 N BROADWAY | BALTIMORE | MD | 21205 | 520595110 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| JOHNS HOPKINS UNIVERSITY SCHOOL OF | ||||||||
| 733 N BROADWAY | BALTIMORE | MD | 21205 | 520595110 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| LA JOLLA INSTITUTE FOR ALLERGY AND | ||||||||
| 9420 ATHENA CIR | LA JOLLA | CA | 92037 | 330328688 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| LUDWIG INSTITUTE FOR CANCER RESEARC | ||||||||
| 666 THIRD AVE 28TH FL | NEW YORK | NY | 10017 | 237121131 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| MASSACHUSETTS GENERAL HOSPITAL | ||||||||
| 55 FRUIT ST | BOSTON | MA | 02114 | 041564655 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| MASSACHUSETTS GENERAL HOSPITAL | ||||||||
| 55 FRUIT ST | BOSTON | MA | 02114 | 041564655 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| MASSACHUSETTS GENERAL HOSPITAL | ||||||||
| 55 FRUIT ST | BOSTON | MA | 02114 | 041564655 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| MASSACHUSETTS GENERAL HOSPITAL | ||||||||
| 55 FRUIT ST | BOSTON | MA | 02114 | 041564655 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| MASSACHUSETTS GENERAL HOSPITAL | ||||||||
| 55 FRUIT ST | BOSTON | MA | 02114 | 041564655 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| MASSACHUSETTS INSTITUTE OF TECHNOLO | ||||||||
| 77 MASSACHUSETTS AVE | CAMBRIDGE | MA | 02139 | 042103594 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| MASSACHUSSETS GENERAL HOSPITAL | ||||||||
| 55 FRUIT STREET | BOSTON | MA | 02114 | 041564655 | 3 | $356,484 | ACCRUAL | RESEARCH GRANT |
| MAYO CLINIC ARIZONA | ||||||||
| 13400 E SHEA BLVD | SCOTTSDALE | AZ | 85259 | 416011702 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| MAYO CLINIC ARIZONA | ||||||||
| 13400 E SHEA BLVD | SCOTTSDALE | AZ | 85259 | 416011702 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| MAYO CLINIC ARIZONA DBA MAYO CLI | ||||||||
| 13400 E SHEA BLVD | SCOTTSDALE | AZ | 85259 | 416011702 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| MAYO CLINIC ARIZONA DBA MAYO CLI | ||||||||
| 13400 E SHEA BLVD | SCOTTSDALE | AZ | 85259 | 416011702 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| MAYO CLINIC ARIZONA | ||||||||
| 13400 E SHEA BLVD | SCOTTSDALE | AZ | 85259 | 416011702 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| MAYO CLINIC ARIZONA | ||||||||
| 13400 E SHEA BLVD | SCOTTSDALE | AZ | 85259 | 416011702 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| MEMORIAL SLOAN KETTERING CANCER CEN | ||||||||
| 1275 YORK AVENUE | NEW YORK | NY | 10065 | 131924236 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| MEMORIAL SLOAN KETTERING CANCER CEN | ||||||||
| 1275 YORK AVENUE | NEW YORK | NY | 10065 | 131924236 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| MEMORIAL SLOAN KETTERING CANCER CEN | ||||||||
| 1275 YORK AVENUE | NEW YORK | NY | 10065 | 131924236 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| MEMORIAL SLOAN KETTERING CANCER CEN | ||||||||
| 1275 YORK AVENUE | NEW YORK | NY | 10065 | 131924236 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| MEMORIAL SLOAN-KETTERING CANCER CEN | ||||||||
| 1275 YORK AVENUE | NEW YORK | NY | 10065 | 131924236 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| MEMORIAL SLOAN-KETTERING CANCER CEN | ||||||||
| 1275 YORK AVENUE | NEW YORK | NY | 10065 | 131924236 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| MEMORIAL SLOAN-KETTERING CANCER CEN | ||||||||
| 1275 YORK AVENUE | NEW YORK | NY | 10065 | 131924236 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| MEMORIAL SLOAN-KETTERING CANCER CEN | ||||||||
| 1275 YORK AVENUE | NEW YORK | NY | 10065 | 131924236 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| MOFFITT CANCER CENTER AND RESEARCH | ||||||||
| 12902 USF MAGNOLIA DR | TAMPA | FL | 33612 | 593238636 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| MOUNT SINAI SCHOOL OF MEDICINE | ||||||||
| 1428 MADISON AVE | NEW YORK | NY | 10029 | 136171197 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| MOUNT SINAI SCHOOL OF MEDICINE | ||||||||
| 1428 MADISON AVE | NEW YORK | NY | 10029 | 136171197 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| MPN RESEARCH FOUNDATION | ||||||||
| 180 N MICHIGAN AVENUE SUITE 1870 | CHICAGO | IL | 60601 | 364330967 | 3 | $400,000 | ACCRUAL | RESEARCH GRANT |
| NEW YORK UNIVERSITY SCHOOL OF MEDIC | ||||||||
| 550 1ST AVENUE | NEW YORK | NY | 10016 | 135562308 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| NEW YORK UNIVERSITY SCHOOL OF MEDIC | ||||||||
| 550 1ST AVENUE | NEW YORK | NY | 10016 | 135562308 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| NEW YORK UNIVERSITY SCHOOL OF MEDIC | ||||||||
| 550 1ST AVENUE | NEW YORK | NY | 10016 | 135562308 | 3 | $1,250,000 | ACCRUAL | RESEARCH GRANT |
| NEW YORK UNIVERSITY SCHOOL OF MEDIC | ||||||||
| 550 1ST AVENUE | NEW YORK | NY | 10016 | 135562308 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| NEW YORK UNIVERSITY SCHOOL OF MEDIC | ||||||||
| 550 FIRST AVE GBH-SC1-47 | NEW YORK | NY | 10016 | 135562308 | 3 | $100,000 | FMV | THERAPY ACCELERATION |
| NORTHWESTERN UNIVERSITY | ||||||||
| 633 CLARK ST | EVANSTON | IL | 60208 | 362167817 | 3 | $297,404 | ACCRUAL | RESEARCH GRANT |
| NORTHWESTERN UNIVERSITY - CHICAGO C | ||||||||
| 750 N LAKE SHORE DR | CHICAGO | IL | 60611 | 362167817 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| NORTHWESTERN UNIVERSITY - CHICAGO C | ||||||||
| 750 N LAKE SHORE DR | CHICAGO | IL | 60611 | 362167817 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| NORTHWESTERN UNIVERSITY - CHICAGO C | ||||||||
| 750 N LAKE SHORE DR | CHICAGO | IL | 60611 | 362167817 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| NORTHWESTERN UNIVERSITY - CHICAGO C | ||||||||
| 750 N LAKE SHORE DR | CHICAGO | IL | 60611 | 362167817 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| NORTHWESTERN UNIVERSITY - CHICAGO C | ||||||||
| 750 N LAKE SHORE DR | CHICAGO | IL | 60611 | 362167817 | 3 | $1,250,000 | ACCRUAL | RESEARCH GRANT |
| OHIO STATE UNIVERSITY | ||||||||
| 281 W LANE AVE | COLUMBUS | OH | 43210 | 316025986 | 3 | $300,000 | ACCRUAL | RESEARCH GRANT |
| OREGON HEALTH & SCIENCE UNIVERSITY | ||||||||
| 3181 SW SAM JACKSON PARK RD | PORTLAND | OR | 97239 | 931176109 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| OREGON HEALTH & SCIENCE UNIVERSITY | ||||||||
| 3181 SW SAM JACKSON PARK RD | PORTLAND | OR | 97239 | 931176109 | 3 | $1,250,000 | ACCRUAL | RESEARCH GRANT |
| OREGON HEALTH & SCIENCE UNIVERSITY | ||||||||
| 0690 SW BANCROFT ST | PORTLAND | OR | 97239 | 931176109 | 3 | $555,500 | FMV | THERAPY ACCELERATION |
| OREGON HEALTH & SCIENCE UNIVERSITY | ||||||||
| 0690 SW BANCROFT ST | PORTLAND | OR | 97239 | 931176109 | 3 | $1,111,000 | FMV | THERAPY ACCELERATION |
| PRESIDENT & FELLOWS OF HARVARD COLL | ||||||||
| MASSACHUSETTS HALL | CAMBRIDGE | MA | 02138 | 042103580 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| PRESIDENT & FELLOWS OF HARVARD COLL | ||||||||
| MASSACHUSETTS HALL | CAMBRIDGE | MA | 02138 | 042103580 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| PRESIDENT & FELLOWS OF HARVARD COLL | ||||||||
| MASSACHUSETTS HALL | CAMBRIDGE | MA | 02138 | 042103580 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| REGENTS OF THE UNIVERSITY OF MICHI | ||||||||
| BOX 223131 | PITTSBURGH | PA | 15251 | 386006309 | 3 | $20,059 | FMV | THERAPY ACCELERATION |
| REGENTS OF THE UNIVERSITY OF MICHI | ||||||||
| BOX 223131 | PITTSBURGH | PA | 15251 | 386006309 | 3 | $168,259 | FMV | THERAPY ACCELERATION |
| REGENTS OF THE UNIVERSITY OF MICHI | ||||||||
| BOX 223131 | PITTSBURGH | PA | 15251 | 386006309 | 3 | $26,587 | FMV | THERAPY ACCELERATION |
| REGENTS OF THE UNIVERSITY OF MICHI | ||||||||
| BOX 223131 | PITTSBURGH | PA | 15251 | 386006309 | 3 | $13,012 | FMV | THERAPY ACCELERATION |
| REGENTS OF THE UNIVERSITY OF MICHI | ||||||||
| BOX 223131 | PITTSBURGH | PA | 15251 | 386006309 | 3 | $286,084 | FMV | THERAPY ACCELERATION |
| REGENTS OF THE UNIVERSITY OF MICHI | ||||||||
| BOX 223131 | PITTSBURGH | PA | 15251 | 386006309 | 3 | $260,211 | FMV | THERAPY ACCELERATION |
| REGENTS OF THE UNIVERSITY OF MICHI | ||||||||
| BOX 223131 | PITTSBURGH | PA | 15251 | 386006309 | 3 | $217,067 | FMV | THERAPY ACCELERATION |
| REGENTS OF THE UNIVERSITY OF MINNES | ||||||||
| 420 JOHH JOHNSTON HALL 101 PLEASA | MINNEAPOLIS | MN | 55455 | 416007513 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| REGENTS OF THE UNIVERSITY OF MINNES | ||||||||
| 420 JOHH JOHNSTON HALL 101 PLEASA | MINNEAPOLIS | MN | 55455 | 416007513 | 3 | $100,000 | ACCRUAL | RESEARCH GRANT |
| RHODE ISLAND HOSPITAL | ||||||||
| 593 EDDY ST | PROVIDENCE | RI | 02903 | 050258954 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| SAINT LOUIS UNIVERSITY | ||||||||
| 221 N GRAND BLVD | ST LOUIS | MO | 63103 | 430654872 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| SLOAN KETTERING INSTITUTE FOR CANCE | ||||||||
| 1275 YORK AVENUE | NEW YORK | NY | 10065 | 131924236 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| SLOAN-KETTERING INSTITUTE FOR CANCE | ||||||||
| 1275 YORK AVENUE | NEW YORK | NY | 10065 | 131924236 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| SLOAN-KETTERING INSTITUTE FOR CANCE | ||||||||
| 1275 YORK AVENUE | NEW YORK | NY | 10065 | 131924236 | 3 | $500,000 | ACCRUAL | RESEARCH GRANT |
| SLOAN-KETTERING INSTITUTE FOR CANCE | ||||||||
| 1275 YORK AVENUE | NEW YORK | NY | 10065 | 131924236 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| SLOAN-KETTERING INSTITUTE FOR CANCE | ||||||||
| 1275 YORK AVENUE | NEW YORK | NY | 10065 | 131924236 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| SLOAN-KETTERING INSTITUTE FOR CANCE | ||||||||
| 1275 YORK AVENUE | NEW YORK | NY | 10065 | 131924236 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| SLOAN-KETTERING INSTITUTE FOR CANCE | ||||||||
| 1275 YORK AVENUE | NEW YORK | NY | 10065 | 131924236 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| SLOAN-KETTERING INSTITUTE FOR CANCE | ||||||||
| 1275 YORK AVENUE | NEW YORK | NY | 10065 | 131924236 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| SLOAN-KETTERING INSTITUTE FOR CANCE | ||||||||
| 1275 YORK AVENUE | NEW YORK | NY | 10065 | 131924236 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| SLOAN-KETTERING INSTITUTE FOR CANCE | ||||||||
| 1275 YORK AVENUE | NEW YORK | NY | 10065 | 131924236 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| ST JUDE CHILDREN'S RESEARCH HOSPIT | ||||||||
| 262 DANNY THOMAS PL | MEMPHIS | TN | 38105 | 620646012 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| STANFORD UNIVERSITY | ||||||||
| 291 CAMPUS DR | STANFORD | CA | 94305 | 941156365 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| STANFORD UNIVERSITY | ||||||||
| 291 CAMPUS DR | STANFORD | CA | 94305 | 941156365 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| STANFORD UNIVERSITY | ||||||||
| 291 CAMPUS DR | STANFORD | CA | 94305 | 941156365 | 3 | $500,000 | ACCRUAL | RESEARCH GRANT |
| STANFORD UNIVERSITY | ||||||||
| 291 CAMPUS DR | STANFORD | CA | 94305 | 941156365 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| STANFORD UNIVERSITY | ||||||||
| 291 CAMPUS DR | STANFORD | CA | 94305 | 941156365 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| STANFORD UNIVERSITY | ||||||||
| 291 CAMPUS DR | STANFORD | CA | 94305 | 941156365 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| STANFORD UNIVERSITY | ||||||||
| 291 CAMPUS DR | STANFORD | CA | 94305 | 941156365 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| STANFORD UNIVERSITY | ||||||||
| PO BOX 44253 | SAN FRANCISCO | CA | 94144 | 941156365 | 3 | $326,076 | FMV | THERAPY ACCELERATION |
| STOWERS INSTITUTE FOR MEDICAL RESEA | ||||||||
| 1000 E 50TH ST | KANSAS CITY | MO | 64110 | 202993509 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| SUNY UPSTATE MEDICAL UNIVERSITY | ||||||||
| 750 E ADAMS ST | SYRACUSE | NY | 13210 | 166038703 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE BOARD OF REGENTS OF THE UNIVERS | ||||||||
| 1860 VAN HISE HALL 1220 LINDEN DR | MADISON | WI | 53706 | 396006492 | 3 | $215,000 | ACCRUAL | RESEARCH GRANT |
| THE BOARD OF TRUSTEES OF THE LELAND | ||||||||
| 291 CAMPUS DR | STANFORD | CA | 94305 | 941156365 | 3 | $268,353 | ACCRUAL | RESEARCH GRANT |
| THE BOARD OF TRUSTEES OF THE LELAND | ||||||||
| 291 CAMPUS DR | STANFORD | CA | 94305 | 941156365 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE BOARD OF TRUSTEES OF THE UNIVER | ||||||||
| 700 S HALSTED ST 2029 | CHICAGO | IL | 60607 | 362177139 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE CHILDREN'S HOSPITAL OF PHILADEL | ||||||||
| 34TH ST CIVIC CENTER BLVD | PHILADELPHIA | PA | 19104 | 232237932 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE CHILDREN'S HOSPITAL OF PHILADEL | ||||||||
| 34TH ST CIVIC CENTER BLVD | PHILADELPHIA | PA | 19104 | 232237932 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE HOSPITAL FOR SPECIAL SURGERY | ||||||||
| 535 E 70TH ST | NEW YORK | NY | 10021 | 136714749 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| THE J DAVID GLADSTONE INSTITUTES | ||||||||
| 88 KEARNY ST SUITE 900 | SAN FRANCISCO | CA | 94108 | 237203666 | 3 | $100,000 | ACCRUAL | RESEARCH GRANT |
| THE OHIO STATE UNIVERSITY | ||||||||
| 281 W LANE AVE | COLUMBUS | OH | 43210 | 316025986 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| THE OHIO STATE UNIVERSITY | ||||||||
| 281 W LANE AVE | COLUMBUS | OH | 43210 | 316025986 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| THE OHIO STATE UNIVERSITY | ||||||||
| 281 W LANE AVE | COLUMBUS | OH | 43210 | 316025986 | 3 | $1,250,000 | ACCRUAL | RESEARCH GRANT |
| THE OHIO STATE UNIVERSITY RESEARCH | ||||||||
| 281 W LANE AVE | COLUMBUS | OH | 43210 | 316025986 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| THE PENNSYLVANIA STATE UNIVERSITY C | ||||||||
| 500 UNIVERSITY DRIVE | HERSHEY | PA | 17033 | 246000376 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 2150 SHATTUCK AVE SUITE 300 | BERKELEY | CA | 94704 | 946002123 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 2150 SHATTUCK AVE SUITE 300 | BERKELEY | CA | 94704 | 946002123 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 2150 SHATTUCK AVE SUITE 300 | BERKELEY | CA | 94704 | 946002123 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 11000 KINROSS AVE SUITE 211 | LOS ANGELES | CA | 90095 | 956006143 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 11000 KINROSS AVE SUITE 211 | LOS ANGELES | CA | 90095 | 956006143 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 11000 KINROSS AVE SUITE 211 | LOS ANGELES | CA | 90095 | 956006143 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 9500 GILMAN DR | LA JOLLA | CA | 92093 | 956006144 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 9500 GILMAN DR | LA JOLLA | CA | 92093 | 956006144 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 9500 GILMAN DR | LA JOLLA | CA | 92093 | 956006144 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 9500 GILMAN DR | LA JOLLA | CA | 92093 | 956006144 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 9500 GILMAN DR | LA JOLLA | CA | 92093 | 956006144 | 3 | $1,250,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 9500 GILMAN DR | LA JOLLA | CA | 92093 | 956006144 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 500 PARNASSUS AVE | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 500 PARNASSUS AVE | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 500 PARNASSUS AVE | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 500 PARNASSUS AVE | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 500 PARNASSUS AVE | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 500 PARNASSUS AVE | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 500 PARNASSUS AVE | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 500 PARNASSUS AVE | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 500 PARNASSUS AVE | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 500 PARNASSUS AVE | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 500 PARNASSUS AVE | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 500 PARNASSUS AVE | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 500 PARNASSUS AVE | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 500 PARNASSUS AVE | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 500 PARNASSUS AVE | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 9500 GILMAN DR | LA JOLLA | CA | 92093 | 956006144 | 3 | $398,316 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | ||||||||
| 11000 KINROSS AVE SUITE 211 | LOS ANGELES | CA | 90095 | 956006143 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF MI | ||||||||
| 500 S STATE ST | ANN ARBOR | MI | 48109 | 386006309 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF MI | ||||||||
| 500 S STATE ST | ANN ARBOR | MI | 48109 | 386006309 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF MI | ||||||||
| 500 S STATE ST | ANN ARBOR | MI | 48109 | 386006309 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF MI | ||||||||
| 500 S STATE ST | ANN ARBOR | MI | 48109 | 386006309 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF MI | ||||||||
| 500 S STATE ST | ANN ARBOR | MI | 48109 | 386006309 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF MI | ||||||||
| 500 S STATE ST | ANN ARBOR | MI | 48109 | 386006309 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF MI | ||||||||
| 500 S STATE ST | ANN ARBOR | MI | 48109 | 386006309 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF MI | ||||||||
| 500 S STATE ST | ANN ARBOR | MI | 48109 | 386006309 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE ROCKEFELLER UNIVERSITY | ||||||||
| 1230 YORK AVENUE | NEW YORK | NY | 10065 | 131624158 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| THE ROCKEFELLER UNIVERSITY | ||||||||
| 1230 YORK AVENUE | NEW YORK | NY | 10065 | 131624158 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| THE ROCKEFELLER UNIVERSITY | ||||||||
| 1230 YORK AVENUE | NEW YORK | NY | 10065 | 131624158 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| THE ROCKEFELLER UNIVERSITY | ||||||||
| 1230 YORK AVENUE | NEW YORK | NY | 10065 | 131624158 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| THE ROCKEFELLER UNIVERSITY | ||||||||
| 1230 YORK AVENUE | NEW YORK | NY | 10065 | 131624158 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| THE ROCKEFELLER UNIVERSITY | ||||||||
| 1230 YORK AVENUE | NEW YORK | NY | 10065 | 131624158 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| THE SCRIPPS RESEARCH INSTITUTE | ||||||||
| 10550 N TORREY PINES RD | LA JOLLA | CA | 92037 | 330435954 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE TRUSTEES OF THE UNIVERSITY OF P | ||||||||
| 1 COLLEGE HALL ROOM 211 | PHILADELPHIA | PA | 19104 | 231352685 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| THE TRUSTEES OF THE UNIVERSITY OF P | ||||||||
| 1 COLLEGE HALL ROOM 211 | PHILADELPHIA | PA | 19104 | 231352685 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| THE TRUSTEES OF THE UNIVERSITY OF P | ||||||||
| 1 COLLEGE HALL ROOM 211 | PHILADELPHIA | PA | 19104 | 231352685 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| THE TRUSTEES OF THE UNIVERSITY OF P | ||||||||
| 1 COLLEGE HALL ROOM 211 | PHILADELPHIA | PA | 19104 | 231352685 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| THE TRUSTEES OF THE UNIVERSITY OF P | ||||||||
| 1 COLLEGE HALL ROOM 211 | PHILADELPHIA | PA | 19104 | 231352685 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| THE TRUSTEES OF THE UNIVERSITY OF P | ||||||||
| 1 COLLEGE HALL ROOM 211 | PHILADELPHIA | PA | 19104 | 231352685 | 3 | $1,250,000 | ACCRUAL | RESEARCH GRANT |
| THE UNIVERSITY OF ALABAMA AT BIRMIN | ||||||||
| 1720 2ND AVE S | BIRMINGHAM | AL | 35233 | 636005396 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| THE UNIVERSITY OF CHICAGO | ||||||||
| 5801 S ELLIS AVENUE | CHICAGO | IL | 60637 | 362177139 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| THE UNIVERSITY OF CHICAGO | ||||||||
| 5801 S ELLIS AVENUE | CHICAGO | IL | 60637 | 362177139 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| THE UNIVERSITY OF NORTH CAROLINA AT | ||||||||
| CB 1350 104 AIRPORT DR SUITE 220 | CHAPEL HILL | NC | 27599 | 566001393 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| THE UNIVERSITY OF NORTH CAROLINA AT | ||||||||
| 104 AIRPORT DRIVE | CHAPEL HILL | NC | 27599 | 566001393 | 3 | $397,026 | ACCRUAL | RESEARCH GRANT |
| THE UNIVERSITY OF TEXAS MD ANDERSON | ||||||||
| 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030 | 746001118 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| THE UNIVERSITY OF TEXAS MD ANDERSON | ||||||||
| 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030 | 746001118 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| TRUSTEES OF DARTMOUTH COLLEGE | ||||||||
| 6010 PARKHURST HALL SUITE 204 | HANOVER | NH | 03755 | 020222111 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| TUFTS MEDICAL CENTER | ||||||||
| 800 WASHINGTON ST | BOSTON | MA | 02111 | 043400617 | 3 | $300,000 | ACCRUAL | RESEARCH GRANT |
| UNIV OF TEXAS HEALTH SCIENCE CENTER | ||||||||
| 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229 | 741586031 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF ARKANSAS FOR MEDICAL | ||||||||
| 4301 WEST MARKHAM | LITTLE ROCK | AR | 72205 | 710236904 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF CA SAN DIEGO - HEALT | ||||||||
| 9500 GILMAN DR DEPT 0012 | LA JOLLA | CA | 92093 | 956006144 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF CALIFORNIA SAN FRANCI | ||||||||
| 500 PARNASSUS AVE | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF CALIFORNIA SAN FRANCI | ||||||||
| 500 PARNASSUS AVE | SAN FRANCISCO | CA | 94143 | 946036493 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF COLORADO AT BOULDER | ||||||||
| SPONSORED PROJECT ACCOUNTING PO BO | DENVER | CO | 80291 | 846000555 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF CONNECTICUT HEALTH CE | ||||||||
| 263 FARMINGTON AVEUE | FARMINGTON | CT | 06032 | 060772160 | 3 | $326,189 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF FLORIDA | ||||||||
| GRINTER HALL PO BOX 115500 | GAINESVILLE | FL | 32611 | 596002052 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF FLORIDA | ||||||||
| GRINTER HALL PO BOX 115500 | GAINESVILLE | FL | 32611 | 596002052 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF FLORIDA | ||||||||
| 219 GINTER HAL | GAINESVILLE | FL | 32611 | 596002052 | 3 | $394,882 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF KANSAS MEDICAL CENTER | ||||||||
| 4350 SHAWNEE MISSION PARKWAY | FAIRWAY | KS | 66205 | 481202402 | 3 | $84,948 | FMV | THERAPY ACCELERATION |
| UNIVERSITY OF MARYLAND BALTIMORE | ||||||||
| 620 W LEXINGTON ST | BALTIMORE | MD | 21201 | 526002033 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF MASSACHUSETTS MEDICAL | ||||||||
| 55 N LAKE AVENUE | WORCESTER | MA | 01655 | 043167352 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF MASSACHUSETTS MEDICAL | ||||||||
| 55 N LAKE AVENUE | WORCESTER | MA | 01655 | 043167352 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF MASSACHUSETTS MEDICAL | ||||||||
| 55 N LAKE AVENUE | WORCESTER | MA | 01655 | 043167352 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF MASSACHUSETTS MEDICAL | ||||||||
| 55 N LAKE AVENUE | WORCESTER | MA | 01655 | 043167352 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF MASSACHUSETTS MEDICAL | ||||||||
| 55 N LAKE AVENUE | WORCESTER | MA | 01655 | 043167352 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF MICHIGAN | ||||||||
| 500 S STATE ST | ANN ARBOR | MI | 48109 | 386006309 | 3 | $241,290 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF MICHIGAN DEPARTMENT O | ||||||||
| 500 S STATE ST | ANN ARBOR | MI | 48109 | 386006309 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF MICHIGAN DEPARTMENT O | ||||||||
| 500 S STATE ST | ANN ARBOR | MI | 48109 | 386006309 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF MINNESOTA - TWIN CITI | ||||||||
| 420 JOHH JOHNSTON HALL 101 PLEASA | MINNEAPOLIS | MN | 55455 | 416007513 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF MINNESOTA TWIN CITIE | ||||||||
| 420 JOHH JOHNSTON HALL 101 PLEASA | MINNEAPOLIS | MN | 55455 | 416007513 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF NORTH CAROLINA AT CHA | ||||||||
| CB 1350 104 AIRPORT DR SUITE 220 | CHAPEL HILL | NC | 27599 | 566001393 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF ROCHESTER | ||||||||
| 515 HYLAN BUILDING RC BOX 270140 | ROCHESTER | NY | 14627 | 160743209 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF TEXAS MD ANDERSON C | ||||||||
| 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030 | 746001118 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF TEXAS MD ANDERSON C | ||||||||
| 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030 | 746001118 | 3 | $500,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF TX MD ANDERSON CANC | ||||||||
| 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030 | 746001118 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF TX MD ANDERSON CANC | ||||||||
| 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030 | 746001118 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF TX MD ANDERSON CANC | ||||||||
| 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030 | 746001118 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF TX MD ANDERSON CANC | ||||||||
| 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030 | 746001118 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF TX MD ANDERSON CANC | ||||||||
| 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030 | 746001118 | 3 | $400,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF UTAH | ||||||||
| 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112 | 876000525 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF UTAH | ||||||||
| 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112 | 876000525 | 3 | $111,715 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF UTAH | ||||||||
| 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112 | 876000525 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF VIRGINIA | ||||||||
| UNIVERSITY OF VIRGINIA SCHOOL OF ME | CHARLOTTESVILE | VA | 22908 | 541682176 | 3 | $100,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF VIRGINIA | ||||||||
| UNIVERSITY OF VIRGINIA SCHOOL OF ME | CHARLOTTESVILE | VA | 22908 | 541682176 | 3 | $100,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF WASHINGTON | ||||||||
| 4333 BROOKLYN AVE 17TH FL UW TOWE | SEATTLE | WA | 98105 | 943079432 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF WASHINGTON | ||||||||
| 4333 BROOKLYN AVE 17TH FL UW TOWE | SEATTLE | WA | 98105 | 943079432 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF WISCONSIN-MADISON | ||||||||
| 21 N PARK ST SUITE 6401 | MADISON | WI | 53715 | 396006492 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| UT SOUTHWESTERN MEDICAL CENTER | ||||||||
| 5323 HARRY HINES BLVD | DALLAS | TX | 75390 | 756002868 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| UT SOUTHWESTERN MEDICAL CENTER | ||||||||
| 5323 HARRY HINES BLVD | DALLAS | TX | 75390 | 756002868 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| UT SOUTHWESTERN MEDICAL CENTER | ||||||||
| 5323 HARRY HINES BLVD | DALLAS | TX | 75390 | 756002868 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| UT SOUTHWESTERN MEDICAL CENTER | ||||||||
| 5323 HARRY HINES BLVD | DALLAS | TX | 75390 | 756002868 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| VANDERBILT UNIVERSITY MEDICAL CENTE | ||||||||
| 1211 MEDICAL CENTER DR | NASHVILLE | TN | 37232 | 620476822 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| VIRGINIA COMMONWEALTH UNIVERSITY | ||||||||
| 821 W FRANKLIN ST | RICHMOND | VA | 23284 | 546001758 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| WAKE FOREST UNIVERSITY HEALTH SCIEN | ||||||||
| 1 MEDICAL CENTER BLVD | WINSTONSALEM | NC | 27103 | 223849199 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| WASHINGTON UNIVERSITY IN ST LOUIS | ||||||||
| 1 BROOKINGS DR | ST LOUIS | MO | 63130 | 430653611 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT |
| WASHINGTON UNIVERSITY OF ST LOUIS | ||||||||
| 660 S EUCLID AVE | ST LOUIS | MO | 63110 | 430653611 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| WASHINGTON UNIVESITY SCHOOL OF MEDI | ||||||||
| 660 EUCLID AVEUNE | ST LOUIS | MO | 63110 | 916001537 | 3 | $399,033 | ACCRUAL | RESEARCH GRANT |
| WHITEHEAD INSTITUTE FOR BIOMEDICAL | ||||||||
| 9 CAMBRIDGE CENTER | CAMBRIDGE | MA | 02142 | 061043412 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| WHITEHEAD INSTITUTE FOR BIOMEDICAL | ||||||||
| 9 CAMBRIDGE CENTER | CAMBRIDGE | MA | 02142 | 061043412 | 3 | $65,000 | ACCRUAL | RESEARCH GRANT |
| WHITEHEAD INSTITUTE FOR BIOMEDICAL | ||||||||
| 9 CAMBRIDGE CENTER | CAMBRIDGE | MA | 02142 | 061043412 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| YALE UNIVERSITY | ||||||||
| 47 COLLEGE ST SUITE 216 | NEW HAVEN | CT | 06510 | 060646973 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| YALE UNIVERSITY | ||||||||
| 47 COLLEGE ST SUITE 216 | NEW HAVEN | CT | 06510 | 060646973 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| YALE UNIVERSITY | ||||||||
| 47 COLLEGE ST SUITE 216 | NEW HAVEN | CT | 06510 | 060646973 | 3 | $100,000 | ACCRUAL | RESEARCH GRANT |
| YALE UNIVERSITY | ||||||||
| 47 COLLEGE ST SUITE 216 | NEW HAVEN | CT | 06510 | 060646973 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| ACETYLON | ||||||||
| SEAPORT CENTER 70 FARGO CENTER | BOSTON | MA | 02210 | 263506788 | $250,000 | FMV | THERAPY ACCELERATION | |
| BECKLOFF ASSOCIATES INC | ||||||||
| 3203 EAST SOLUTIONS CENTER | CHICAGO | IL | 60677 | 480842223 | $44,891 | FMV | THERAPY ACCELERATION | |
| BECKLOFF ASSOCIATES INC | ||||||||
| 3203 EAST SOLUTIONS CENTER | CHICAGO | IL | 60677 | 480842223 | $11,053 | FMV | THERAPY ACCELERATION | |
| BECKLOFF ASSOCIATES INC | ||||||||
| 3203 EAST SOLUTIONS CENTER | CHICAGO | IL | 60677 | 480842223 | $17,505 | FMV | THERAPY ACCELERATION | |
| BECKLOFF ASSOCIATES INC | ||||||||
| 3203 EAST SOLUTIONS CENTER | CHICAGO | IL | 60677 | 480842223 | $10,392 | FMV | THERAPY ACCELERATION | |
| BECKLOFF ASSOCIATES INC | ||||||||
| 3203 EAST SOLUTIONS CENTER | CHICAGO | IL | 60677 | 480842223 | $16,427 | FMV | THERAPY ACCELERATION | |
| BECKLOFF ASSOCIATES INC | ||||||||
| 3203 EAST SOLUTIONS CENTER | CHICAGO | IL | 60677 | 480842223 | $25,000 | FMV | THERAPY ACCELERATION | |
| BECKLOFF ASSOCIATES INC | ||||||||
| 3203 EAST SOLUTIONS CENTER | CHICAGO | IL | 60677 | 480842223 | $100,000 | FMV | THERAPY ACCELERATION | |
| BIO THERYX INC | ||||||||
| 20 CABIN RIDGE RD | CHAPPAQUA | NY | 10514 | 260501342 | $250,000 | FMV | THERAPY ACCELERATION | |
| CELATOR PHARMACEUTICALS INC | ||||||||
| 200 PRINCETON SOUTH CORPORATE CENTE | EWING | NJ | 08628 | 202680869 | $267,145 | FMV | THERAPY ACCELERATION | |
| CHARLES RIVER LABORATORIES INC | ||||||||
| GPO BOX 27812 | NEW YORK | NY | 10087 | 760509980 | $36,053 | FMV | THERAPY ACCELERATION | |
| CHARLES RIVER LABORATORIES INC | ||||||||
| GPO BOX 27812 | NEW YORK | NY | 10087 | 760509980 | $42,750 | FMV | THERAPY ACCELERATION | |
| CHARLES RIVER LABORATORIES INC | ||||||||
| GPO BOX 27812 | NEW YORK | NY | 10087 | 760509980 | $72,050 | FMV | THERAPY ACCELERATION | |
| CHARLES RIVER LABORATORIES INC | ||||||||
| GPO BOX 27812 | NEW YORK | NY | 10087 | 760509980 | $20,816 | FMV | THERAPY ACCELERATION | |
| CHARLES RIVER LABORATORIES INC | ||||||||
| GPO BOX 27812 | NEW YORK | NY | 10087 | 760509980 | $6,210 | FMV | THERAPY ACCELERATION | |
| CHARLES RIVER LABORATORIES INC | ||||||||
| GPO BOX 27812 | NEW YORK | NY | 10087 | 760509980 | $12,820 | FMV | THERAPY ACCELERATION | |
| CHARLES RIVER LABORATORIES INC | ||||||||
| GPO BOX 27812 | NEW YORK | NY | 10087 | 760509980 | $13,877 | FMV | THERAPY ACCELERATION | |
| CHARLES RIVER LABORATORIES INC | ||||||||
| GPO BOX 27812 | NEW YORK | NY | 10087 | 760509980 | $35,658 | FMV | THERAPY ACCELERATION | |
| CHARLES RIVER LABORATORIES INC | ||||||||
| GPO BOX 27812 | NEW YORK | NY | 10087 | 760509980 | $614,490 | FMV | THERAPY ACCELERATION | |
| CONSTELLATION PHARMACEUTICALS | ||||||||
| 215 FIRST STREET | CAMBRIDGE | MA | 02142 | 261741721 | $1,000,000 | FMV | THERAPY ACCELERATION | |
| CONSTELLATION PHARMACEUTICALS | ||||||||
| 215 FIRST STREET | CAMBRIDGE | MA | 02142 | 261741721 | $250,000 | FMV | THERAPY ACCELERATION | |
| CONSTELLATION PHARMACEUTICALS | ||||||||
| 215 FIRST STREET | CAMBRIDGE | MA | 02142 | 261741721 | $1,500,000 | FMV | THERAPY ACCELERATION | |
| KP PHARMACEUTICAL TECHNOLOGY | ||||||||
| 1212 W RAPPEL AVE | BLOOMINGTON | IN | 47404 | 352025958 | $20,588 | FMV | THERAPY ACCELERATION | |
| NANOSYN INC | ||||||||
| 3100 CENTRAL EXPRESSWAY | SANTA CLARA | CA | 95051 | 860909295 | $1,064,250 | FMV | THERAPY ACCELERATION | |
| NANOSYN INC | ||||||||
| 3100 CENTRAL EXPRESSWAY | SANTA CLARA | CA | 95051 | 860909295 | $455,740 | FMV | THERAPY ACCELERATION | |
| SHAPE PHARMACEUTICALS INC | ||||||||
| 47 THORNDIKE STREET | CAMBRIDGE | MA | 02141 | 263714475 | $300,000 | FMV | THERAPY ACCELERATION | |
| SHAPE PHARMACEUTICALS INC | ||||||||
| 47 THORNDIKE STREET | CAMBRIDGE | MA | 02141 | 263714475 | $241,000 | FMV | THERAPY ACCELERATION | |
| STEMLINE THERAPEUTICS INC | ||||||||
| 750 LEXINGTON AVE | NEW YORK | NY | 10022 | 450522567 | $1,000,000 | FMV | THERAPY ACCELERATION | |
| VALOR BIOTHERAPEUTICS | ||||||||
| 8800 HSC PARKWAY | BRYAN | TX | 77807 | 461883738 | $400,000 | FMV | THERAPY ACCELERATION | |
| VALOR BIOTHERAPEUTICS | ||||||||
| 8800 HSC PARKWAY | BRYAN | TX | 77807 | 461883738 | $400,000 | FMV | THERAPY ACCELERATION | |
| VELESCO PHARMACEUTICAL SERVICE | ||||||||
| 46701 N COMMERCE CENTER DRIVE | PLYMOUTH | MI | 48170 | 261330932 | $20,160 | FMV | THERAPY ACCELERATION | |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 109 | Total501c3OrgCnt |
| Total Other Org | 12 | TotalOtherOrgCnt |
Grants Other Asst To Indiv In US GrantsOtherAsstToIndivInUSGrp (7 entries)
| Grant TypeGrantTypeTxt | RecipientRecipientCnt | Cash GrantCashGrantAmt |
|---|---|---|
| PATIENT FINANCIAL AID | 25236 | $2,523,615 |
| COPAY ASSISTANCE CLL | 2120 | $4,453,691 |
| COPAY ASSISTANCE LYMPHOMA | 7905 | $17,443,678 |
| COPAY ASSISTANCE MDS | 1478 | $3,320,299 |
| COPAY ASSISTANCE MYELOMA | 6976 | $23,593,351 |
| COPAY ASSISTANCE MANTEL | 161 | $435,000 |
| PATIENT TRAVEL ASSISTNCE | 618 | $154,500 |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | SCHEDULE I, PAGE 1, PART I, LINE 2 | FormAndLineReferenceDesc |
| Explanation | FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS,EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. PATIENT FINANCIAL AID: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR MANY EXPENSES RELATED TO THEIR TREATMENT. SOMETIMES PATIENTS HAVE TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE TREATMENT EXPENSES. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS HAS ESTABLISHED A PATIENT FINANCIAL AID PROGRAM THAT PROVIDES APPLICANTS, WHO RESIDE IN THE US AND HAVE A BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA. CO-PAY ASSISTANCE: PATIENT APPLICATIONS ARE PROCESSED ON A FIRST COME, FIRST SERVED BASIS. ELIGIBLE PATIENTS MUST RESIDE IN THE UNITED STATES OR PUERTO RICO, HAVE A PROGRAM COVERED BLOOD CANCER DIAGNOSIS CONFIRMED BY A PHYSICIAN, MAINTAIN MEDICAL/PRESCRIPTION INSURANCE AND HAVE HOUSEHOLD INCOME AT OR BELOW 500% OF THE US FEDERAL POVERTY LEVEL AS ADJUSTED BY HOUSEHOLD SIZE AND COST OF LIVING INDEX. PATEINTS MUST PROVIDE PROOF OF INSURANCE AND INCOME. QUALIFYING PATIENTS ARE APPROVED FOR A TWELVE MONTH COVERAGE PERIOD. PATIENT TRAVEL ASSISTANCE: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR TRANSPORTATION TO GET TO THEIR PROVIDERS, E.G. DOCTORS, HOSPITALS, TRANSPLANT CENTERS, AND RESEARCH OR CLINICAL TRIAL CENTERS. SOMETIMES PATIENTS HAVE TO TRAVEL OUT-OF-STATE TO GET THEIR PRESCRIBED AND RECOMMENDED TREATMENTS, OFTENTIMES RESULTING IN PATIENTS HAVING TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS ESTABLISHED THE TRAVEL ASSISTANCE PROGRAM WHICH PROVIDES APPLICANTS, WHO ARE US CITIZENS OR PERMANENT RESIDENTS, HAVE AN ANNUAL INCOME AT OR BELOW 500% OF THE FEDERAL POVERTY LEVEL (FPL) AND HAVE A CONFIRMED BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Compensation Committee | Yes (X) | CompensationCommitteeInd |
| Independent Consultant | Yes (X) | IndependentConsultantInd |
| Form990 Of Other Organizations | Yes (X) | Form990OfOtherOrganizationsInd |
| Compensation Survey | Yes (X) | CompensationSurveyInd |
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | Yes (true) | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | Yes (true) | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | false | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | false | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | false | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | false | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | false | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | Yes (true) | AnyNonFixedPaymentsInd |
| Initial Contract Exception | false | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (8 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount |
|---|---|---|---|---|---|---|
| JOHN E WALTER | ||||||
| PRES&CEO TERM 2/2014 | $606,473 | $21,886 | $32,130 | $31,216 | $691,705 | |
| LOUIS J DEGENNARO | ||||||
| PRESIDENT & CEO | $380,451 | $23,165 | $71,667 | $22,640 | $540,507 | $42,584 |
| JAMES T NANGLE | ||||||
| SVP&CFO TERM 9/2013 | $155,599 | $252,803 | $15,606 | $26,767 | $450,775 | |
| LISA STOCKMON | ||||||
| EVP-CHIEF MKTG OFFIC | $294,428 | $18,027 | $18,749 | $17,075 | $384,279 | $36,000 |
| GEORGE J OMIROS | ||||||
| EVP-CHIEF CAMP&FIELD | $299,361 | $20,357 | $25,500 | $19,753 | $379,971 | $15,000 |
| MARK VELLECA | ||||||
| CHIEF POLICY & ADVOC | $289,161 | $13,161 | $17,351 | $30,429 | $371,102 | $21,000 |
| MARK ROITHMAYR | ||||||
| CHIEF DEVELOPMENT OF | $301,719 | $18,995 | $25,806 | $346,520 | ||
| BRIAN ROSEN | ||||||
| CHIEF POLICY & ADVOC | $256,998 | $12,208 | $5,594 | $28,055 | $316,146 | $13,291 |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| SCHEDULE J, PAGE 1, PART I, LINE 4 | LOUIS J. DEGENNARO 0 46,667 0 JAMES T. NANGLE 238,870 0 0 |
| SCHEDULE J, PAGE 1, PART I, LINE 7 | BONUSES WERE PAID BASED ON THE ACHIEVEMENT OF GROSS REVENUE EXCEEDING BUDGTED GROSS REVENUE, EMPLOYEE INDIVIDUAL PERFORMANCE AND OTHER METRICS. BONUSES WERE CAPPED ACCORDING TO LLS'S POLICY. THESE AMOUNTS ARE REPORTED ON SCHEDULE J PART II, COLUMN (B) (II). |
Schedule M IRS990ScheduleM
Securities Publicly Traded SecuritiesPubliclyTradedGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Contribution | 122 | ContributionCnt |
| Noncash Contributions Rpt F990 | $890,755 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | MARKET VALUE | MethodOfDeterminingRevenuesTxt |
Food Inventory FoodInventoryGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Contribution | 51 | ContributionCnt |
Other Non Cash Contri Table OtherNonCashContriTableGrp (3 entries)
| Non Cash CheckboxNonCashCheckboxInd | DescDesc | ContributionContributionCnt |
|---|---|---|
| Yes (X) | PRINTED ITEMS | 13 |
| Yes (X) | FURNITURE&EQUIP | 4 |
| Yes (X) | VARIOUS | 60 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Any Property That Must Be Held | false | AnyPropertyThatMustBeHeldInd |
| Review Process Unusual NC Gifts | Yes (true) | ReviewProcessUnusualNCGiftsInd |
| Third Parties Used | false | ThirdPartiesUsedInd |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| SCHEDULE M, PAGE 1, PART I, LINE 33 | LLS ONLY RECORDS DONATED SECURITIES AS REVENUE. ALL OTHER ITEMS FOR WHICH COLUMN A IS CHECKED ARE NOT RECORDED AS REVENUE OR EXPENSE BECAUSE THEY WOULD NOT HAVE BEEN PURCHASED HAD THEY NOT BEEN DONATED, AND ARE IMMATERIAL IN AMOUNT RELATIVE TO THE STATEMENTS OF LLS. |
| SCHEDULE M, PAGE 2, PART II | PART I, COLUMN (B) LLS IS REPORTING THE NUMBER OF CONTRIBUTIONS FOR EACH OF THE ITEMS IN PART I, NOT THE NUMBER OF INDIVIDUAL ITEMS. |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (17 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, PAGE 2, PART III, LINE 4A | TO DATE, LLS HAS INVESTED ALMOST 1 BILLION IN RESEARCH AIMED AT HELPING ALL BLOOD CANCER PATIENTS LIVE BETTER, LONGER LIVES. WE WILL CONTINUE TO SUPPORT RESEARCH THROUGH OUR INNOVATIVE AND INTEGRATED FUNDING PROGRAMS, UNTIL EVERY PATIENT HAS A SAFE AND EFFECTIVE THERAPY. IN FISCAL YEAR 2014, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 7 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 78 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. OUR CRITICAL ROLE LLS PROGRAMS ACCELERATE RELEVANT RESEARCH OUTCOMES BY: - BUILDING A FOCUSED RESEARCH WORK-FORCE: ASSURING THE NEXT ROUND OF BREAKTHROUGHS REQUIRES THAT YOUNG INVESTIGATORS BE ENCOURAGED TO WORK IN BLOOD CANCER RESEARCH FIELDS. - TURNING DISCOVERIES INTO NEW THERAPIES: FUNDAMENTAL NEW FINDINGS CAN BE TRANSLATED INTO SAFE AND EFFECTIVE TREATMENTS THAT CAN ULTIMATELY PROLONG AND ENHANCE PATIENT LIVES. - SUPPORTING SYNERGY: LARGE GRANTS AND CONTRACTS ENABLE SCIENTISTS IN ACADEMIA AND THE PRIVATE-SECTOR TO COLLABORATE, COMBINING RESOURCES AND EXPERTISE TO PRODUCE MORE AND FASTER ADVANCES. - FILLING A VOID: RESEARCH PROJECTS THAT ARE HIGH-RISK AND/OR ADDRESS RARE CANCERS ARE LESS LIKELY TO BE FUNDED BY GOVERNMENT AGENCIES OR FOR-PROFIT COMPANIES, BUT MAY PROVIDE IMPORTANT ADVANCES. - SPEEDING NEW TREATMENTS TO PATIENTS: PARTNERING WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES CAN ADVANCE PROMISING THERAPIES THROUGH CLINICAL TESTING, FASTER. PAST ADVANCES MADE WITH LLS RESEARCH FUNDING GENEROUS DONORS HAVE HELPED LLS SUPPORT RESEARCH THAT HAS ALREADY BENEFITED BLOOD CANCER PATIENTS AND MANY OTHERS. ADVANCES INCLUDE: - MULTI-DRUG THERAPIES THAT ARE MORE EFFECTIVE THAN TREATMENTS WITH SINGLE ANTI-CANCER AGENTS, - BONE MARROW / STEM CELL TRANSPLANTATION AND SUPPORTIVE CARE TREATMENTS FOR PATIENTS WHO RELAPSE DESPITE THE BEST AVAILABLE THERAPY, - TESTS THAT DISTINGUISH SPECIFIC CHARACTERISTICS OF PARTICULAR BLOOD CANCERS FOR ACCURATE DIAGNOSIS OF CANCER SUBTYPES, AND FOR "RISK STRATIFICATION" TO SELECT AN OPTIMAL THERAPY. TARGETED THERAPY RESEARCH DISCOVERING THE MOLECULAR ABNORMALITIES THAT CAUSE PARTICULAR TYPES OF BLOOD CANCER HAS BEEN USEFUL IN DIAGNOSIS AND RISK STRATIFICATION, AND IN NEW "TARGETED DRUG" DEVELOPMENT. LLS-FUNDED INVESTIGATORS HAVE HELPED ADVANCE MOLECULARLY TARGETED TREATMENTS THAT CAN SELECTIVELY KILL BLOOD CANCER CELLS VERSUS NORMAL CELLS. MANY OF THESE NEW TREATMENTS BENEFIT NOT ONLY BLOOD CANCER PATIENTS, BUT ALSO PATIENTS WITH OTHER DISEASES. FOR EXAMPLE: - GLEEVEC IS FDA-APPROVED FOR PATIENTS OF ALL AGES WITH CHRONIC MYELOID LEUKEMIA (CML), AND IS ALSO APPROVED FOR PATIENTS WITH ONE FORM OF ACUTE LYMPHOID LEUKEMIA (ALL), MYELODYSPLASTIC SYNDROMES (MDS), MYELOPROLIFERATIVE DISORDERS AND RARE FORMS OF STOMACH AND SKIN CANCERS. RELATED DRUGS, SPRYCEL AND TASIGNA, ARE APPROVED FOR PATIENTS WHO DO NOT BENEFIT FROM GLEEVEC. ONE OR MORE OF THESE DRUGS ARE ALSO SHOWING PROMISE FOR PATIENTS WITH VARIOUS LYMPHOMAS, ACUTE MYELOID LEUKEMIA (AML), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND OTHER CANCERS, INCLUDING BRAIN, BREAST, HEAD-AND-NECK, LUNG, PANCREATIC, AND PROSTATE CANCERS, AND PATIENTS WITH OTHER DISEASES INCLUDING ALZHEIMER'S, ASTHMA AND PULMONARY HYPERTENSION. - RITUXAN WAS THE FIRST FDA-APPROVED, ANTI-CANCER ANTIBODY DRUG, DEVELOPED FOR PATIENTS WITH FORMS OF B-CELL NON-HODGKIN LYMPHOMA (NHL). IT IS NOW ALSO APPROVED FOR CLL PATIENTS AND AS A "MAINTENANCE" THERAPY FOR FOLLICULAR LYMPHOMA PATIENTS, AND SHOWING PROMISE FOR PATIENTS WITH ALL AND AFTER STEM CELL TRANSPLANTATION. IN ADDITION, IT IS APPROVED FOR TREATING PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS AND TWO OTHER TYPES OF AUTOIMMUNE DISEASES. A RELATED ANTIBODY DRUG, ARZERRA, IS APPROVED FOR CLL PATIENTS AND SHOWING WIDER PROMISE. - VELCADE, THALIDOMID AND REVLIMID ARE FDA-APPROVED FOR PATIENTS WITH MYELOMA AND ARE ALSO HELPING SOME PATIENTS WITH HODGKIN LYMPHOMA AND NHL. KRYPOLIS WAS RECENTLY APPROVED FOR MYELOMA PATIENTS FOR WHOM AT LEAST TWO PRIOR THERAPIES WERE INSUFFICIENT. ONE OR MORE OF THESE DRUGS ARE NOW BEING TESTED FOR PATIENTS WITH T-CELL AND B-CELL FORMS OF LYMPHOMA, ACUTE LEUKEMIAS, AS WELL AS AIDS-RELATED KAPOSI SARCOMA AND BRAIN, BREAST, COLORECTAL, HEAD-AND-NECK, KIDNEY, LIVER, LUNG, OVARIAN AND PROSTATE CANCERS, AND ALZHEIMER'S DISEASE. - ISTODAX, ZOLINZA, DACOGEN AND VIDAZA TARGET SMALL CHEMICAL, "EPIGENETIC" CHANGES. THE FIRST TWO DRUGS ARE APPROVED FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS; THE LATTER DRUGS ARE APPROVED FOR MDS PATIENTS. ONE OR MORE OF THESE DRUGS ARE BEING TESTED FOR PATIENTS WITH ALL, AML, CML, CLL, MYELOMA AND FORMS OF NHL, AFTER STEM CELL TRANSPLANTATION, AND FOR PATIENTS WITH BREAST, BRAIN, KIDNEY, COLORECTAL, HEAD-AND-NECK, LUNG, STOMACH, PROSTATE AND OVARIAN CANCERS, MELANOMA AS WELL AS SICKLE CELL DISEASE AND PERSISTENT HIV INFECTIONS. - ADCETRIS WAS APPROVED IN 2011, AND IN JANUARY 2012. IT IS AN ANTIBODY- DRUG CONJUGATE THAT COMBINES AN ANTI-CD30 ANTIBODY AND THE CYTOTOXIC DRUG MONOMETHYL AURISTATIN E (MMAE). IT IS AN ANTI-NEOPLASTIC AGENT USED IN THE TREATMENT OF HODGKIN LYMPHOMA AFTER FAILURE OF AUTOLOGOUS STEM CELL TRANSPLANT OR THOSE WHO ARE NOT ELIGIBLE FOR ASCT AFTER FAILURE OF AT LEAST 2 MUTIAGEN CHEMOTHERAPY REGIMENS. ADCETRIS WAS ALSO APPROVED FOR SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA WITH FAILURE OF AT LEAST ONE PRIOR TREATMENT. - GAZYVA IS A HUMANIZED MONOCLONAL ANTIBODY USED AS A COMBINATION TREATMENT WITH CHLORAMBUCIL TO TREAT PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA. IT WAS APPROVED BY THE FDA IN NOVEMBER 2013 AND BY THE EHA IN JULY 2014. - IMBRUVICA IS AN ORAL SMALL MOLECULE INHIBITOR AGIANST BTK KINASE. IT WAS FIRST APPROVED BY THE US FDA ON NOVEMBER 13, 2013 FOR THE TREATMENT OF MANTLE CELL LYMPHOMA PATIENTS WHO HAVE RECIEVED AT LEAST ONE PRIOR TREATMENT. ON FEB. 12, 2014 THE US FDA EXPANDED THE APPROVED USE OF THE DRUG TO CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ADDITIONALLY, IT RECEIVED FURTHER EXPANSION TO TREAT 17P DELETION IN CLL WITH OR WITHOUT PRIOR THERAPY. - ZYDELIG IS AN ORAL SMALL MOLECULE INHIBITOR THAT BLOCKS THE DELTA ISOFORM OF THE ENZYME PHOSPHOINOSITIDE 3-KINASE. IT WAS APPROVED BY THE FDA IN JULY 2014 TO TREAT RELAPSED/REFRACTORY CLL IN COMBINATION WITH RITUXAN. IT WAS ALSO APPROVED TO USE AS A MONOTHERAPY FOR RELAPSED MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA. OTHER ACTIVE RESEARCH DIRECTIONS LLS-FUNDED RESEARCHERS ARE ALSO EXPLORING OTHER AREAS OF RESEARCH THAT HOLD PROMISE FOR PATIENTS: - NOVEL STEM CELL TRANSPLANTATION PROCEDURES: THESE INCLUDE SO-CALLED "MINI" TRANSPLANTS THAT USE LESS TOXIC PRE-TRANSPLANT TREATMENTS AND ENGINEERED DONOR CELLS THAT HELP REDUCE POST-TRANSPLANT COMPLICATIONS, MAKING THESE POTENTIALLY CURATIVE TREATMENTS AVAILABLE TO MORE PATIENTS. - IMMUNOTHERAPIES: INCLUDING ANTIBODIES, VACCINES AND ENGINEERED IMMUNE CELLS, THESE TARGETED THERAPIES HELP A PATIENT'S IMMUNE SYSTEM FIGHT INFECTIONS AND KILL RESIDUAL CANCER CELLS, PROLONGING REMISSIONS, AND PERHAPS ONE DAY REPLACING TOXIC CHEMOTHERAPIES. - DIAGNOSTICS: NEW TECHNOLOGIES MAKE IT POSSIBLE TO CHARACTERIZE THE ABNORMALITIES IN INDIVIDUAL CANCER CASES IN MOLECULAR DETAIL. THIS INFORMATION CAN BE USED TO HELP CHOOSE THE BEST POSSIBLE TREATMENT FOR EACH PATIENT, ESPECIALLY AS MORE TARGETED THERAPIES BECOME AVAILABLE. - QUALITY OF LIFE RESEARCH: THESE STUDIES INCREASE OUR UNDERSTANDING OF HOW SPECIFIC TREATMENTS CAN CAUSE DEBILITATING SIDE-EFFECTS, INCLUDING LATE-EFFECTS, AND WHICH PATIENTS ARE AT RISK FOR DEVELOPING THESE COMPLICATIONS, SO THAT THEY CAN BE BETTER MANAGED OR EVEN PREVENTED. DRIVING RESEARCH TO ADDRESS UNMET MEDICAL NEEDS LLS CONTINUES TO SOLICIT AND SUPPORT RESEARCH FOCUSED ON IMPROVING BLOOD CANCER PATIENTS' QUALITY OF LIFE AFTER TODAY'S CURATIVE THERAPIES. ALSO IN 2014, FOR THE THIRD YEAR, LLS ACTIVELY RECRUITED RESEARCH PROPOSALS IN SIX OTHER UNDERDEVELOPED RESEARCH AREAS IN WHICH PROGRESS IS LIKELY TO IMPROVE OUTCOMES FOR PATIENTS WITH PARTICULARLY URGENT NEEDS. NEW RESEARCH IS FOCUSED ON: - DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES FOR PATIENTS WITH NON- CUTANEOUS T-CELL LYMPHOPROLIFERATIVE DISORDERS - DEVELOP NOVEL TARGETED THERAPIES FOR CLL PATIENTS, WITH REAL CURATIVE POTENTIAL - DEVELOP NOVEL TREATMENT STRATEGEIES FOR MDS AND AML PATIENTS - DEVELOP NOVEL TARGETED THERAPIES FOR PATIENTS WITH HIGH-RISK MYELOMA - DEVELOPMENT OF NEW-TARGETED THERAPIES FOR INDOLENT LYMPHOMA PATIENTS - DEFINE GENETIC/MOLECULAR PREDISPOSITIONS TO LONG-TERM AND LATE-TERM EFFECTS ASSOCIATED WITH STANDARD THERAPIES IN PEDIATRIC ALL AND APPLY THIS INFORAMTION TO IMPROVE PATIENT OUTCOMES THE THERAPY ACCELERATION PROGRAM THIS STRATEGIC INITIATIVE WAS LAUNCHED IN 2007 TO MOVE NEW TREATMENTS AND DIAGNOSTICS THROUGH PRECLINICAL DEVELOPMENT AND CLINICAL TRIALS, FASTER. USING MILESTONE-DRIVEN CONTRACTS AND WORKING IN CONCERT WITH ACADEMIC INVESTIGATORS, MEDICAL CENTERS AND COMPANIES, LLS IS FURTHER BRIDGING THE GAP BETWEEN DISCOVERY AND HUMAN APPLI |
| FORM 990, PAGE 2, PART III, LINE 4B | PROFESSIONAL AND PATIENT EDUCATION PROGRAMS, PUBLICATIONS AND THE LLS WEBSITE. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. LLS PUBLISHES AN ANNUAL COMPILATION OF DATA AVAILABLE FOR BLOOD CANCERS, INCLUDING THE ESTIMATED NUMBERS OF NEW BLOOD CANCER CASES AND DEATHS, THE MOST RECENT STATISTICS AVAILABLE FOR INCIDENCE, MORTALITY AND SURVIVAL; AND CURRENT AND ACCURATE INFORMATION ABOUT SYMPTOMS, RISK FACTORS AND TREATMENT. PUBLICATIONS AN EXTENSIVE CATALOG OF EDUCATION MATERIALS IS OFFERED FREE-OF-CHARGE TO PATIENTS AND HEALTHCARE PROFESSIONALS. EACH YEAR, LLS DISTRIBUTES BOOKLETS, BROCHURES, FACT SHEETS, EDUCATION PROGRAM TRANSCRIPTS AND DVDS THROUGH THE INFORMATION RESOURCE CENTER AND LLS CHAPTERS. MANY MATERIALS ARE ALSO AVAILABLE TO VIEW AND DOWNLOAD AT WWW.LLS.ORG/RESOURCECENTER. DOWNLOADABLE MATERIALS ARE AVAILABLE IN ENGLISH, SPANISH AND FRENCH. - 742,148 PRINTED BOOKLETS, BROCHURES, FACT SHEETS, EDUCATION PROGRAM TRANSCRIPTS AND DVDS DISTRIBUTED IN 2014. FINANCIAL ASSISTANCE IN 2014, A COMBINED 51,924,134 WAS DISBURSED TO PATIENTS THROUGH THE LLS PATIENT FINANCIAL AID (2,523,615),CO-PAY ASSISTANCE PROGRAMS (49,246,019) AND THE LLS PATIENT TRAVEL ASSISTANCE PROGRAM (154,500). PATIENT FINANCIAL ASSISTANCE PROGRAMS FOR MORE THAN 47 YEARS, LLS HAS HELPED PATIENTS DEMONSTRATING SIGNIFICANT NEED TO OBTAIN FINANCIAL ASSISTANCE TO COVER A PORTION OF THEIR TREATMENT COSTS. THE LLS PATIENT FINANCIAL ASSISTANCE PROGRAM PROVIDES A LIMITED AMOUNT OF FINANCIAL ASSISTANCE TO HELP PATIENTS WITH SIGNIFICANT FINANCIAL NEED AND WHO ARE UNDER A DOCTOR'S CARE FOR A CONFIRMED BLOOD CANCER DIAGNOSIS. PATIENT FINANCIAL ASSISTANCE FUNDS ARE SUBJECT TO AVAILABILITY. - 25,854 PATIENTS RECEIVED PATIENT FINANCIAL ASSISTANCE IN 2014. CO-PAY ASSISTANCE PROGRAM THIS CO-PAY ASSISTANCE PROGRAM HELPS PATIENTS WITH MANY KINDS OF BLOOD CANCERS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO-PAYMENT OBLIGATIONS RELATED TO TREATING THEIR CANCER. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUND AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. FOR MORE INFORMATION CALL, (877) LLS-COPAY (877) 557-2672 OR VISIT WWW.LLS.ORG/COPAY. - 18,640 PATIENTS RECEIVED LLS CO-PAY ASSISTANCE IN 2014 COMMUNITY PROGRAMS EACH LLS CHAPTER OFFICE IS STAFFED WITH A PATIENT SERVICES MANAGER (PSM) WHO OVERSEES SERVICES TO PATIENTS AND THEIR FAMILIES, CAREGIVERS AND HEALTHCARE PROFESSIONALS. PSMS ARE HEALTHCARE PROFESSIONALS, OFTEN WITH A BACKGROUND IN ONCOLOGY NURSING OR SOCIAL WORK. PSMS SERVE AS LIAISONS WITH COMMUNITY AND REGIONAL ONCOLOGY/HEMATOLOGY HEALTHCARE PROFESSIONALS AND TREATMENT CENTERS.COMMUNITY-BASED EDUCATION AND OUTREACH, SUPPORT AND PUBLIC POLICY AND ADVOCACY PROGRAMS ARE AVAILABLE. - 27,459 PATIENT AND CAREGIVER PARTICIPANTS ACROSS THE US IN 2014 - 10,798 HEALTHCARE PROFESSIONAL PARTICIPANTS ACROSS THE US IN 2014 PROGRAMS FOR CHILDREN AND YOUNG ADULTS THE TRISH GREENE BACK TO SCHOOL PROGRAM FOR CHILDREN WITH CANCER FOCUSES ON INCREASING COMMUNICATION AMONG HEALTHCARE PROFESSIONALS, PARENTS, PATIENTS AND SCHOOL PERSONNEL TO SUPPORT CHILDREN, ADOLESCENTS AND YOUNG ADULTS LIVING WITH CANCER. PRINTED LITERATURE, VIDEOS AND OTHER MATERIALS TO AID THE PROCESS ARE AVAILABLE IN COMMUNITIES THROUGHOUT THE US AND CANADA VIA LLS CHAPTER OFFICES. THE PROGRAM INCLUDES STAYING CONNECTED: FACILITATING THE LEARNING EXPERIENCE DURING AND AFTER CANCER TREATMENT. THIS EDUCATION PROGRAM FOR SCHOOL PERSONNEL, HEALTHCARE PROFESSIONALS AND PARENTS DESCRIBES PHYSICAL, COGNITIVE AND PSYCHOSOCIAL SHORT-AND LONG-TERM EFFECTS THAT CHILDREN, ADOLESCENTS AND YOUNG ADULTS MAY EXPERIENCE DURING AND AFTER TREATMENT. THE PROGRAM OFFERS GUIDANCE AND NUMEROUS RESOURCES TO HELP CHILDREN, ADOLESCENTS AND YOUNG ADULTS CONTINUE THEIR EDUCATION DURING AND AFTER TREATMENT. - 1,075 SCHOOL PERSONNEL, HEALTHCARE PROFESSIONALS AND PARENTS PARTICIPATED IN THE 22 STAYING CONNECTED PROGRAMS ACROSS THE US AND CANADA IN 2014. FAMILY SUPPORT GROUPS LLS HAS DEVELOPED 344 FAMILY SUPPORT GROUPS AT CHAPTERS THROUGHOUT THE US AND CANADA. LLS ALSO HAS 618 VOLUNTEER SUPPORT GROUP FACILITATORS WITH BACKGROUNDS IN ONCOLOGY NURSING OR SOCIAL WORK. GROUPS ARE GUIDED BY TWO VOLUNTEER ONCOLOGY HEALTH PROFESSIONALS, PROVIDING INFORMATION AND SUPPORT AND ENCOURAGING GREATER COMMUNICATION AMONG PATIENTS, FAMILIES, FRIENDS AND HEALTHCARE PROFESSIONALS. - 13,811 PARTICIPANTS IN FAMILY SUPPORT GROUPS ACROSS THE US IN 2014 PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM FIRST CONNECTION IS A PROGRAM THAT LINKS NEWLY DIAGNOSED PATIENTS TO A PEER VOLUNTEER WHO HAS EXPERIENCED A SIMILAR DIAGNOSIS. A TRAINED PATIENT-VOLUNTEER CURRENTLY IN REMISSION CONTACTS THE NEW PATIENT TO SHARE INFORMATION AND SUPPORT. THIS PROGRAM IS AVAILABLE THROUGH LLS CHAPTERS. - 5,616 FIRST CONNECTIONS ACROSS THE US IN 2014. |
| FORM 990, PAGE 2, PART III, LINE 4C | NURSES AND HEALTH EDUCATORS WHO PROVIDE HELP WITH DISEASE, TREATMENT AND CLINICAL TRIAL INFORMATION AND SUPPORT. LLS INFORMATION SPECIALISTS CONDUCT CLINICAL-TRIAL SEARCHES TO HELP PATIENTS WORK WITH THEIR DOCTORS TO FIND OUT ABOUT SPECIFIC CLINICAL TRIALS. PATIENTS, FAMILIES AND HEALTHCARE PROFESSIONALS MAY SPEAK TO AN INFORMATION SPECIALIST AT (800) 955-4572 MONDAY THROUGH FRIDAY, 9 A.M. TO 9 P.M., ET, EMAIL INFOCENTER@LLS.ORG OR CHAT ONE-ON-ONE VIA THE LLS WEBSITE. THE INFORMATION RESOURCE CENTER OFFERS TRANSLATION SERVICES IN MORE THAN 165 LANGUAGES. - 48,326 INQUIRIES IN 2014 THE LLS WEBSITE THE LLS WEBSITE, WWW.LLS.ORG, FULFILLS A WIDE VARIETY OF EDUCATION AND INFORMATION NEEDS. VISITORS CAN PERSONALIZE THEIR WEB PAGES TO THEIR LOCATION TO KEEP CURRENT WITH DISEASE-SPECIFIC UPDATES AND COMMUNITY EDUCATION AND SUPPORT ACTIVITIES. THE WEBSITE PROVIDES ACCESS TO LLS PROGRAMS AND SERVICES, INCLUDING CO-PAY ASSISTANCE, THE MOST CURRENT AND ACCURATE INFORMATION AND STATISTICS, WEEKLY FACILITATED ONLINE CHATS, NATIONAL TELEPHONE AND WEB EDUCATION PROGRAMS, PUBLICATIONS IN ENGLISH, SPANISH AND FRENCH, AND CLINICAL-TRIAL SEARCHES VIA AN ONLINE CLINICAL- TRIAL SEARCH SERVICE THAT OFFERS PATIENTS AND CAREGIVERS IMMEDIATE ACCESS TO LISTINGS OF BLOOD CANCER CLINICAL TRIALS. PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS CAN INTERACT WITH LLS AND ONE ANOTHER THROUGH SOCIAL NETWORKING, PODCASTS AND ENEWSLETTERS. NATIONAL TELEPHONE/ WEB EDUCATION PROGRAMS LLS SPONSORS TELEPHONE AND WEB EDUCATION PROGRAMS FOR PATIENTS, CAREGIVERS, SURVIVORS AND HEALTHCARE PROFESSIONALS ABOUT LEUKEMIA, LYMPHOMA, MYELOMA AND MYELODYSPLASTIC SYNDROMES. IN 2014, 9 LLS NATIONAL EDUCATION PROGRAMS FEATURED DISEASE-SPECIFIC UPDATES AND INFORMATION ABOUT SUPPORT AND TREATMENT OPTIONS FROM WORLD RENOWNED CLINICAL EXPERTS. OPPORTUNITIES ARE PROVIDED TO ASK QUESTIONS OF EXPERTS DURING THESE PROGRAMS. THESE PROGRAMS OFFER CONTINUING EDUCATION CREDITS FOR NURSES AND SOCIAL WORKERS. LLS ALSO SPONSORS A RANGE OF PROFESSIONAL EDUCATION PROGRAMS. RECENT PROGRAMS EXPLORED THE ADMINISTRATION AND MANAGEMENT OF CURRENT THERAPIES FOR HEMATOLOGIC MALIGNANCIES AND COMMUNICATION AMONG PRIMARY CARE PROVIDERS AND HEMATOLOGISTS/ONCOLOGISTS IN MANAGING PATIENTS WITH HEMATOLOGIC CANCER. UPCOMING PROGRAMS ARE POSTED AT WWW.LLS.ORG/PROGRAMS AND ARCHIVES OF PAST PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PASTPROGRAMS. PROFESSIONAL EDUCATION PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PROFESSIONALED. LLS ALSO OFFERS DISEASE-SPECIFIC WEBCASTS PRESENTED BY WORLD RENOWNED CLINICAL EXPERTS. THESE CAN BE ACCESSED AT WWW.LLS.ORG/WEBCASTS. |
| FORM 990, PAGE 2, PART III, LINE 4D | D) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. |
| FORM 990, PART V, LINE 4B | CANADA |
| FORM 990, PAGE 6, PART VI, LINE 4 | IN 2013, THE LLS BOARD OF DIRECTORS (BOD) AND THE BOARD OF REPRESENTATIVES (BOR) AUTHORIZED CHANGES TO THE CHAPTERS' INVOLVEMENT IN THE LLS GOVERNANCE. PURSUANT TO THE CHANGES, THE LLS BYLAWS WERE AMENDED IN JANUARY 2014 TO REFLECT THAT THE CHAPTERS, ACTING THROUGH THE CHAPTER CHAIR ASSEMBLY WILL REPLACE THE BOR AND WILL RETAIN OVERSIGHT OVER THE LLS ACTIVITIES AND PROGRAMS AT THE CHAPTER LEVEL. ALL OTHER VOTING RIGHTS AFFORDED TO MEMBERS UNDER THE NEW YORK NOT-FOR-PROFIT CORPORATION LAW (NPCL), INCLUDING THE RIGHT TO ELECT THE LLS ELECTED DIRECTORS, WILL NOW BE VESTED IN A SECOND CLASS OF MEMBERS COMPRISED OF THE LLS BOARD OF DIRECTORS. IN ADDITION, THE LLS BYLAWS WERE AMENDED TO REFLECT THE REQUIREMENTS OF THE NEW YORK NON-PROFIT REVITALIZATION ACT OF 2013. THE ACT REQUIRES LLS TO EXERCISE INCREASED OVERSIGHT OF ITS AUDIT AS WELL AS ITS ACCOUNTING AND FINANCIAL REPORTING PROCESSES. THE AMENDMENT INCLUDES ADDITIONAL DUTIES THAT THE AUDIT COMMITTEE MUST CARRY OUT TO COMPLY WITH THE ACT. |
| FORM 990, PAGE 6, PART VI, LINE 6 | THE MEMBERS OF LLS CONSIST OF ONE ELECTED REPRESENTATIVE FROM EACH CHAPTER. |
| FORM 990, PAGE 6, PART VI, LINE 7A | THE LLS BOARD OF DIRECTORS ELECT THE ELECTED DIRECTORS AND HAVE ALL OF THE OTHER VOTING RIGHTS AFFORDED TO MEMBERS UNDER THE NEW YORK NOT-FOR-PROFIT CORPORATION LAW. |
| FORM 990, PAGE 6, PART VI, LINE 7B | SIGNIFICANT DECISIONS AFFECTING THE CHAPTERS REQUIRE AN APPROVING VOTE BY THE CHAPTER DELEGATES. DECISIONS NOT SIGNIFICANTLY AFFECTING THE CHAPTERS DO NOT REQUIRE APPROVAL FROM THE CHAPTER DELEGATES. |
| FORM 990, PAGE 6, PART VI, LINE 11B | THE FORM 990 WAS PREPARED BY THE LLS FINANCE DEPARTMENT AND WAS REVIEWED BY THE CAO & CFO, SR. VICE PRESIDENT OF FINANCE, AND KPMG FOR COMMENT AND SUGGESTED REVISIONS. THE FORM 990 WAS THEN PROVIDED TO THE AUDIT COMMITTEE, WHICH IS A COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWED THE 990 AND PROVIDED INPUT PRIOR TO FILING. THE 990 WAS POSTED TO THE BOARD BOOKS SITE AND WAS FORMALLY APPROVED BY THE AUDIT COMMITTEE ON JANUARY 29, 2015 AND AT THE FULL BOARD MEETING ON JANUARY 30, 2015. |
| FORM 990, PAGE 6, PART VI, LINE 12C | ALL EMPLOYEES, BOARD OF DIRECTORS MEMBERS, BOARD OF REPRESENTATIVES MEMBERS, CHAPTER BOARD MEMBERS, FAMILY SUPPORT GROUP FACILITATORS, AND TNT COACHES ARE REQUIRED TO REVIEW THE CONFLICT OF INTEREST POLICY ON AN ANNUAL BASIS AND SUBMIT A SIGNED FORM ACKNOWLEDGING THAT THEY HAVE REVIEWED THE POLICY AND DISCLOSED ANY CONFLICTS OF INTEREST. ALL FORMS ARE COLLECTED AND THE AUDIT COMMITTEE REVIEWS ANY FORMS DISCLOSING A POSSIBLE CONFLICT OF INTEREST AND DETERMINES WHETHER OR NOT A CONFLICT EXISTS. PART VI, LINE 12 C: ALL EMPLOYEES, BOARD OF DIRECTORS MEMBERS, BOARD OF REPRESENTATIVES ARE RECUSED FROM ANY DISCUSSION WHERE A CONFLICT OF INTEREST EXISTS. ANY QUESTIONS REGARDING COI WILL GO TO THE AUDIT COMMITTEE. |
| FORM 990, PAGE 6, PART VI, LINE 15A | THE EXECUTIVE COMMITTEE, COMPRISED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS, REVIEWS AND MONITORS THE CHIEF EXECUTIVE OFFICER'S PERFORMANCE AND COMPENSATION. THE COMMITTEE OBTAINED A SURVEY OF OTHER NOT-FOR-PROFIT ORGANIZATIONS' COMPENSATION RANGES AND SET THE CHIEF EXECUTIVE'S SALARY COMMENSURATELY. THE MOST RECENT SURVEY WAS CONDUCTED IN 2013. THE REVIEW WAS DOCUMENTED IN THE EXECUTIVE COMMITTEE'S MINUTES. |
| FORM 990, PAGE 6, PART VI, LINE 15B | THE EXECUTIVE COMMITTEE, COMPRISED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS, REVIEWED A SURVEY OF OTHER NOT-FOR-PROFIT ORGANIZATIONS' COMPENSATION RANGES IN 2013 AND COMPARED THIS TO THE OTHER OFFICER'S SALARY AND DETERMINED THAT IT WAS APPROPRIATE. THE REVIEW WAS DOCUMENTED IN THE EXECUTIVE COMMITTEE'S MINUTES. |
| FORM 990, PAGE 6, PART VI, LINE 17 | ILLINOIS, INDIANA, KANSAS, KENTUCKY, LOUISIANA, MASSACHUSETTS, MARYLAND, MAINE, MICHIGAN, MINNESOTA, MISSOURI, MISSISSIPPI, NEW HAMPSHIRE, NEW JERSEY, NEW MEXICO, NEBRASKA, NEW YORK, OHIO, OKLAHOMA, OREGON, PENNSYLVANIA, PUERTO RICO, RHODE ISLAND, SOUTH CAROLINA, TENNESSEE, UTAH, VIRGINIA, WASHINGTON, WISCONSIN, WEST VIRGINIA |
| FORM 990, PAGE 6, PART VI, LINE 19 | THE LEUKEMIA & LYMPHOMA SOCIETY, INC. MAKES ITS ANNUAL FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON ITS WEBSITE AT WWW.LLS.ORG. ITS GOVERNING DOCUMENTS ARE MADE AVAILABLE, WHEN CHANGES ARE MADE, AS PART OF THE 990 AVAILABLE FOR PUBLIC INSPECTION. ANY IDENTIFIED CONFLICTS OF INTEREST ARE DISCLOSED IN THE 990. |
| FORM 990, PART XI, LINE 9 | LLS CANADA REVENUE 12,662,047 LSRP CONTRIBUTION -58,002 ROUNDING 1 LLS CANADA EXPENSES -11,853,901 FOREIGN CURRENCY TRANSALATION ADJUSTMENT -153,433 ROUNDING 4 WRITE-OFF OF CONTRIBUTIONS RECEIVABLE -3,507,289 GRANT REFUND EXPENSED IN PRIOR YEAR 304,286 |
| FORM 990, PART XI, LINE 9 | CHANGE IN NET ASSETS LLS CANADA -724,448 LSRP CONNTRIBUTION 58,002 FINANCIAL STATEMENT ROUNDING -101 FOREIGN CURRENCY TRANSLATION 153,433 UNREALIZED CHANGE ON INVESTMENTS -6,349,371 WRITE-OFF OF CONTRIBUTIONS RECEIVABLES 3,507,289 GRANT REFUND EXPENSED IN PRIOR YEAR -304,286 CHANGE IN NET ASSETS PER FORM 990 (PART XI, LINE 3) -7,102,295 |
Schedule R IRS990ScheduleR
Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp (3 entries)
| Address Line1ForeignAddress/AddressLine1 | CityForeignAddress/City | CountryForeignAddress/Country | Postal CodeForeignAddress/PostalCode | Primary ActivitiesPrimaryActivitiesTxt | Legal Domicile Foreign CountryLegalDomicileForeignCountryCd | Business Name Line1DirectControllingEntityName/BusinessNameLine1 | Controlled OrganizationControlledOrganizationInd | Address Line1USAddress/AddressLine1 | CityUSAddress/City | StateUSAddress/State | ZIP CodeUSAddress/ZIPCode | EINEIN | Legal Domicile StateLegalDomicileStateCd | Exempt Code SectionExemptCodeSectionTxt | Public Charity StatusPublicCharityStatusTxt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| THE LLS OF CANADA | |||||||||||||||
| 804 2 LANSING SQUARE | TORONTO | CA | M2J4P8 | PART VII | CA | LLS INC | Yes (true) | ||||||||
| THE LLS RESEARCH PROGRAMS INC | |||||||||||||||
| PART VII | LLS INC | Yes (true) | 1311 MAMARONECK AVENUE | WHITE PLAINS | NY | 10605 | 133470494 | DE | 501C3 | 11B | |||||
| THE LLS RESEARCH FOUNDATION | |||||||||||||||
| PART VII | LLS INC | Yes (true) | 1311 MAMARONECK AVENUE | WHITE PLAINS | NY | 10605 | 133709252 | DE | 501C3 | 11B | |||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Receipt Of Int Annts Rnts Rylts | false | ReceiptOfIntAnntsRntsRyltsInd |
| Gift Grnt Or Cap Contri To Oth Org | false | GiftGrntOrCapContriToOthOrgInd |
| Gift Grnt Cap Contri From Oth Org | Yes (true) | GiftGrntCapContriFromOthOrgInd |
| Loans Or Guarantees To Other Org | Yes (true) | LoansOrGuaranteesToOtherOrgInd |
| Loans Or Guarantees From Oth Org | false | LoansOrGuaranteesFromOthOrgInd |
| Div Related Organization | false | DivRelatedOrganizationInd |
| Asset Sale To Other Org | false | AssetSaleToOtherOrgInd |
| Asset Purchase From Other Org | false | AssetPurchaseFromOtherOrgInd |
| Asset Exchange | false | AssetExchangeInd |
| Rental Of Facilities To Oth Org | false | RentalOfFacilitiesToOthOrgInd |
| Rental Of Fclts From Oth Org | false | RentalOfFcltsFromOthOrgInd |
| Perform Of Services For Oth Org | false | PerformOfServicesForOthOrgInd |
| Perform Of Services By Other Org | false | PerformOfServicesByOtherOrgInd |
| Sharing Of Facilities | Yes (true) | SharingOfFacilitiesInd |
| Paid Employees Sharing | Yes (true) | PaidEmployeesSharingInd |
| Reimbursement Paid To Other Org | false | ReimbursementPaidToOtherOrgInd |
| Reimbursement Paid By Other Org | false | ReimbursementPaidByOtherOrgInd |
| Transfer To Other Org | false | TransferToOtherOrgInd |
| Transfer From Other Org | false | TransferFromOtherOrgInd |
Transactions Related Org TransactionsRelatedOrgGrp (3 entries)
| Transaction TypeTransactionTypeTxt | InvolvedInvolvedAmt | Method Of Amount DeterminationMethodOfAmountDeterminationTxt |
|---|---|---|
| THE LEUKEMIA & LYMPHOMA SOCIETY | ||
| D | $87,012 | COST |
| OF CANADA | ||
| THE LLS RESEARCH PROGRAMS INC | ||
| C | $58,002 | COST |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | SCHEDULE R | FormAndLineReferenceDesc |
| Explanation | THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA CARRIES OUT THE SAME PRIMARY ACTIVITIES AS THE LEUKEMIA & LYMPHOMA SOCIETY, INC. IN CANADA. THE LEUKEMIA SOCIETY RESEARCH PROGRAMS, INC. AND THE LEUKEMIA RESEARCH FOUNDATION, INC. SUPPORT THE ACTIVITIES OF THE LEUKEMIA & LYMPHOMA SOCIETY, INC. | ExplanationTxt |
Comments